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ABSTRACT 
Danielle D. Durham: Insurance Status and Diagnostic Follow-Up Disparities in  
Breast Cancer Screening 
(Under the direction of Whitney R. Robinson) 
 
 Screening mammography’s effectiveness may be reduced if women do not receive 
timely diagnostic follow-up after a positive mammogram. Lack of insurance may pose 
challenges to adequate follow-up. The objectives of this study were 1) to describe clinical 
follow-up after a positive screening mammogram, 2) to assess the association between 
insurance status and time to initial diagnostic follow-up after a positive screening 
mammogram, and 3) to assess the association between insurance status and receipt of biopsy. 
With data from a North Carolina population-based registry of breast imaging and cancer 
outcomes between 1995-2010, we used Cox proportional hazards regression modeling and 
multivariate logistic modeling to evaluate the association between insurance status and 
follow-up. The most common diagnostic resolution pathways following a positive screening 
mammogram were: 1) diagnostic mammography only (72%); 2) diagnostic mammography, 
ultrasound (11%); and 3) diagnostic mammography, biopsy (7%). In the adjusted model for 
women <65 years, uninsured women experienced a longer time to initiation of diagnostic 
follow-up (hazard ratio (HR) =0.47 (95% confidence interval (95% CI)) =0.25-0.89) versus 
women with private insurance. There was an increased odds of these uninsured women not 
meeting the CDC guideline for follow-up within 60 days (1.59, 95% CI (1.31-1.94).	Women 
under 65 with Medicare & Medicaid were more likely to have experienced a pathway 
including biopsy (OR 1.68, 95% CI 1.05-2.68) when compared to those with private 
iv 
insurance. Among women ages 65+, women with private insurance alone experienced a 
faster time to follow-up (adjusted HR=2.09, 95% CI=1.27-3.44) compared to women with 
Medicare combined with private insurance. Approximately 10% of women had no follow-up 
by 365 days. Women over 65 with private insurance were less likely to have experienced a 
pathway including biopsy when compared to those with Medicare and private insurance (OR 
0.53, 95% CI 0.35-0.79). 
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CHAPTER 1: REVIEW OF THE LITERATURE 
Breast Cancer Incidence, Mortality, and Burden  
In the U.S., breast cancer incidence began decreasing in 2000 1. Though incidence is 
declining, breast cancer is the most commonly diagnosed cancer among women in the U.S. 
and is the second leading cause of cancer death 2. Breast cancer accounts for more than 
200,000 new cases and over 39,000 deaths annually 2. In North Carolina, over 7,500 women 
were expected to be diagnosed with breast cancer in 20133. About 1,300 deaths were 
attributed to breast cancer among North Carolinians in 20114. There are differences in 
incidence by race; when compared to white women, black women have lower incidence of 
breast cancer. 
Trends in mortality due to breast cancer demonstrate a decline beginning in the 
1990s. Even with steady declines in mortality due to breast cancer, there are differences in 
mortality by race. Regardless of age, when compared to white women black women have an 
increased mortality rate due to breast cancer 1. Early detection of breast cancer via screening 
mammography has been shown to decrease mortality from breast cancer 4-6. Research 
indicates that this observed reduction in mortality may not be due entirely to early detection 
via mammography 7. Other studies point toward mammography as a vehicle for over-
diagnosis of breast cancer 8. Regardless of these opposing opinions in the field, breast cancer 
screening via mammography remains the accepted and most common form of early detection 
of breast cancer for women.
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Mammography  
Mammography uses ionizing radiation or x-rays of the breast tissue to create images. 
The procedure is normally performed in an outpatient setting and consists of placing the 
breast between two plates to flatten the tissues for viewing. This compression of the tissue 
helps to spread the tissue out for a clearer image that the radiologist can read. Routine 
procedures include top and side views of each breast and include breast tissue from the 
nipple to the pectoral muscle 1. Additional components of a mammogram, such as additional 
views of the breast, are dependent upon a multitude of patient factors including age, family 
history, and patient risk profile (comorbidities, expression of BRCA 1/2 gene, etc.) 3. 
Most masses and changes in the breast tissue can be viewed on a mammogram. 
Figure 1 displays the particular characteristics of a radiographic image of normal breast 
tissue.  
	
Figure 1. Mammographic Image of the Female Breast 
http://www.ochsner.org/services/radiology_breast_imaging/ 
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Mammography for Breast Cancer Screening in the U.S. 
Mammography for breast cancer screening is a widely accepted method of early 
breast cancer detection 7. It is recommended for routine use among women who do not 
exhibit signs or symptoms of breast cancer. This would include women who are free from 
symptoms such as breast pain, palpable lumps, or nipple discharge 4. The goal of screening 
mammography is to identify cancerous masses or lesions at early stages, particularly those 
masses or lesions that are not palpable during a routine clinical breast examination or self-
breast examination. Routine screening mammography has been associated with a reduction in 
breast cancer mortality among women 40-75 years of age 4, 7. An estimated 60% of breast 
cancers are detected via screening mammography, highlighting its importance in breast 
cancer detection 9, 10. In a national study the majority of breast cancer survivors reported that 
their cancer was detected via screening mammography 9.  
Mammography has been in use for about 30 years and has undergone technical 
advancements over time. These advancements include specialized equipment designed 
specifically for mammography to deliver the lowest dose of radiation possible as well as use 
of the highest quality x-ray imaging. In addition to identifying breast cancer, screening 
mammography can be used to identify other conditions of the breast including cysts, 
calcifications, benign masses, inflammation and injury. 
Guidelines for Mammography Screening in the US 
In 2009 The United Stated Preventive Services Task Force (USPSTF) updated its 
recommended screening guidelines for mammography. Previously the USPSTF 
recommended that women over the age of 40 have a screening mammogram every 1-2 years. 
The updated guidelines include recommendations for specific age groups of women. Women 
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40-49 are no longer recommended to receive routine screening. Women 50-74 should receive 
a screening mammogram every two years. The USPSTF provides no recommendation for 
women 75 years of age and older 1, 4. The American Cancer Society (ACS), however, 
recommends an annual mammogram beginning at age 40. Additionally, The ACS 
recommends that women who are at higher risk because of family history, genetics, etc. 
should be screened with MRI and mammography 2. In order to record results of 
mammography imaging, a standard reporting system is used. 
Breast Imaging Reporting and Data System (BI-RADS) 
A radiologist analyzes the images produced by the mammogram for lesions. The 
radiologist interprets the image of the breast as either benign or suspicious of malignancy and 
in need of follow-up. The results are reported using the Breast Imaging Reporting and Data 
System (BI-RADS). BIRADS is a standardized method accepted by The American College 
of Radiology (ACR) for reporting mammography results 11. The Mammography Quality 
Standards Act (MQSA) of 1997 requires that results of all mammograms to be reported using 
the BI-RADS reporting system.  Mammograms are determined to be positive or negative 
based on the radiologists’ interpretation using BI-RADS. A mammogram is scored on a scale 
from 0-6. The scoring assessment by BI-RADS category is displayed in Table 1.  
Table 1. Breast Imaging Reporting and Data System (BI-RADS) 
BIRADS Category Assessment 
0 Incomplete Needs additional 
Imaging Evaluation 
1 Negative 
2 Benign 
3 Probably Benign 
4 Suspicious 
5 Highly Suspicious of Malignancy 
6 Known Biopsy Proven Malignancy 
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According to the BIRADS classification schema, a mammogram is considered to be 
positive if the BI-RADS score is 0, 4, or 5.  A BI-RADS score of 3 with recommendation for 
biopsy or further evaluation is also considered as a positive result. A score of 1, 2 or 3 with 
no recommendation for biopsy or further evaluation is considered negative 12. 
Diagnostic Mammography 
A diagnostic mammogram is performed on women who have a positive screening 
mammogram result or those who present with breast symptoms (pain, palpable lump/mass 
upon examination, change in breast size and/or shape, or nipple discharge or thickening). A 
diagnostic mammogram may include additional images and views of the breast tissue when 
compared to a screening mammogram.  
Diagnostic Follow-up and Resolution of Screening Mammography 
The importance of diagnostic follow-up 
The screening literature largely focuses on maximizing breast cancer screening rates 
through the use of community-based interventions 13. Two important, but less studied 
dimensions of screening effectiveness that impact disease mortality are diagnostic follow-up 
time and diagnostic resolution 14. Approximately 10% of screening mammograms require 
additional follow-up imaging and about 2% require a confirmatory biopsy 15. 
Defining Follow-up and Diagnostic Resolution 
Diagnostic resolution is defined as the time between a positive screening 
mammogram result and the determination of a positive or negative cancer diagnosis. 
Diagnostic follow-up is defined as the time from a positive screening mammogram to first 
follow-up procedure or diagnostic imaging examination. Figure 2 shows a generalized 
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progression from screening mammography to diagnostic resolution and finally diagnostic 
follow-up. 
 
 
 
 
Though diagnostic follow-up time is important it is difficult to fully enumerate. There 
are some challenges inherent in accurately identifying a positive cancer diagnosis or a 
benign/negative result in administrative databases. These include a lag in the reporting times 
of cancer registries, patients lost to follow-up either via failure to comply with follow-up 
recommendations or receiving care at a different facility or in a different site where capture 
may not be possible.  
Current Recommendations for Follow-up after a Positive Screening Mammogram 
Breast imaging and reporting data system 
Though the BIRADS assessment provides guidelines for follow-up assessment, it 
does not specify a timeframe for all follow-up assessments outside of the ‘probably benign’ 
assessment category. The CDC guidelines do not differentiate the follow-up timeframe. All 
positive screening mammogram results should be resolved within 60 days. Table 2 briefly 
summarizes the recommendations based on BIRADS assessment categories. 
	
Screening 
Mammogram 
Diagnostic Follow-up 
(Diagnostic 
Mammogram, Breast 
Ultrasound, MRI, 
Biopsy) 
Diagnostic 
Resolution 
(Return to screening 
or receive breast 
cancer diagnosis) 
Time Time 
Figure 2. Generalized Steps of the Breast Cancer Screening Process Including Diagnostic 
Follow-up and Diagnostic Resolution 
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Table 2. Categorization of Mammogram using BIRADS and Clinical Management 
Recommendation 
BIRADS 
Category 
Assessment Screening Mammogram 
Result 
Clinical Management 
Recommendation 
0 Incomplete Needs 
additional Imaging 
Evaluation 
Positive Review prior studies 
and/or complete 
additional imaging 
1 Negative Negative Continue Routine 
screening 
2 Benign Continue Routine 
screening 
3 Probably Benign With follow-up 
recommendation=Positive 
Short term follow-up 
mammogram at 6 
months, then every 6-12 
months for 1-2 years 
4 Suspicious Positive Perform biopsy, 
preferably needle 
biopsy 
5 Highly Suspicious of 
Malignancy 
Biopsy and treatment as 
necessary 
6 Known Biopsy 
Proven Malignancy 
Assure that treatment in 
completed 
Adapted from Eberl et al 200616 
The National Comprehensive Cancer Network 
The National Comprehensive Cancer Network (NCCN) is an organization consisting 
of various member institutions such as cancer hospitals with the mission of improving the 
quality and effectiveness of cancer care. NCCN consensus guidelines for clinical 
management of patients undergoing breast cancer screening via mammography are arranged 
by BIRADS category (Figures 3 & 4)17. According to these guidelines, women with a 
BIRADS negative screening mammogram will return to the routine screening population. As 
indicated in the figures, those women with BIRADS positive screening mammograms or 
mammograms that the radiologist deems require additional evaluation will receive additional 
imaging and/or biopsy.  
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Both NCCCN and BIRADS provide recommendations for each level of clinical 
assessment, including benign and suspicious malignancy. The only assessment category that 
is given a definitive time table is probably benign or BIRADS category 3. This category is 
recommended for follow-up at 6 months post-screen. In Figures 1 and 2, the category 
‘mammographic evaluation’ often includes both screening and diagnostic imaging. Imaging 
may consist of screening mammography, diagnostic mammography, breast ultrasound, breast 
MRI, and other specialized imaging techniques. Definitions for these procedures are 
presented in Table 3. 
Other recommendations for follow-up after positive screening mammography 
The American College of Radiology (ACR) recommends women needing follow-up 
must be notified of this within 30 days of reading a positive screening mammogram result 18. 
Guidelines from the Centers for Disease Control (CDC) recommend women should receive 
diagnostic follow-up and begin treatment within 60 days of a positive screening mammogram 
result 19, 20. 
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Figure 3. National Comprehensive Cancer Network Breast Cancer Screening and Diagnosis 
Guidelines 
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Figure 4. National Comprehensive Cancer Network Breast Cancer Screening and Diagnosis 
Guidelines, continued 
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Table 3. Study Definitions of Diagnostic Follow-up Procedures 
Modality Description 
Mammography Film or digital x-ray images are taken of 
the breast 
Ultrasound High frequency sound waves are 
transmitted though the breast tissue 
Magnetic Resonance Imaging (MRI) Uses magnets and radio waves to create 
cross-sectional images of the breast 
Biopsy or fine needle aspirate Cells or tissue are removed from the 
breast and viewed via microscopy by a 
pathologist 
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Figure 5. Conceptual Model of the Impact of Patient and Healthcare System Factors on 
Diagnostic Follow-up after a Positive Screening Mammogram 
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Delays in Follow-up after a Positive Mammogram 
In the extant literature, the reported time from positive screening mammogram until 
diagnostic follow-up studied ranges from a few days to 6 months 21-28. Currently however, 
the only U.S. guideline regarding the time in which follow-up should occur comes from the 
Centers for Disease Control and Prevention (CDC). The CDC Performance Indicators 
recommends that women with a positive screening mammogram complete diagnostic work-
up within 60 days 19, 29. Much of the existing literature uses this designation to assess delay in 
follow-up after a positive screening mammogram. For example, a national study of a breast 
and cervical cancer screening program found that 20% of women did not receive diagnostic 
follow-up within 60 days of a positive screening mammogram 29. Other studies of follow-up 
after a positive screening mammogram result report that 20-40% of women fall outside of the 
CDC guidelines or receive no follow-up after a positive screening mammogram result 19, 29-32.  
Diagnostic Follow-up Pathways 
It is possible for a patient to experience multiple imaging studies and/or biopsy before 
the positive screening mammogram is resolved. These can be thought of as pathways to 
follow-up. Completing multiple diagnostic tests or proceeding through a series of tests 
(diagnostic pathway) after a positive screening mammogram may increase the amount of 
time it will take a patient to reach diagnostic resolution. A “delay” in diagnostic resolution 
may indeed be appropriate if the patient is progressing through clinical management routines 
based on radiologist recommendation and guidelines. Thus, it may not be critical to count the 
total number of days until diagnostic follow-up and resolution after a positive screening 
mammogram and compare this to the CDC guidelines. Instead, it is our opinion that women 
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should be assessed on the various pathways to diagnostic follow-up while taking their 
individual personal factors into account.  
To our knowledge, one study has addressed the issue of multiple pathways or series 
of procedures for diagnostic follow-up and its impact on timing 33. The most common 
diagnostic follow-up procedures from this study and their definitions are presented in Table 
3. Using data from five mammography registries in the Breast Cancer Surveillance 
Consortium (BCSC), the authors looked specifically at variations in diagnostic pathways by 
imaging modality (digital or film screening mammography). The authors found that 
differences in diagnostic pathways after positive screening mammogram between the 
imaging modalities were minimal. Variability in diagnostic pathways was observed across 
facilities performing mammograms indicating recommendation of follow-up by specific 
radiologists may play a role in patient’s follow-up pathways after a positive screening 
mammogram result.    
Disparities in Diagnostic Follow-up after Positive Screening Mammogram 
 Though breast cancer mortality rates have declined over the past 10 years, mortality 
disparities exist for women of minority groups and those of low socioeconomic status (SES). 
Women of low-SES and minority, particularly African-American women, are less likely to 
receive screening mammography, 34 present with more advanced disease, and are more likely 
to receive delayed care and experience increased wait time, than others after a positive 
mammogram 21-24, 35-50. Studies suggest extended time until follow-up varies by racial/ethnic 
group with African American women experiencing the longest delays when compared to White 
women 44, 49, 51. Additionally, persons living in rural areas have greater barriers (i.e. distance to 
facility, limited service availability) to receiving cancer care 52, 53. 
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Untimely follow-up after a positive breast cancer screening mammogram may 
contribute to disparities in breast cancer outcomes and subsequently mortality. Specifically, 
follow-up times of 3-6 months have been associated with larger tumor size and reduced 
survival 14, 34, 54, 55. 
Factors Contributing to Time to Diagnostic Follow-up after a Positive Screening 
Mammogram 
A multitude of factors may contribute to diagnostic follow-up time after a positive 
screening mammogram result. Prior studies have investigated demographic patient factors 
such as race, education, and rural/urban residence that influence diagnostic follow-up time, 
often with limited ability to examine racial subgroups due to either small sample sizes or 
homogenous populations 56. Studies also identify a variety of healthcare system barriers (i.e. 
adequate communication and referral by physician, facility type and size, etc.) that minority 
women and women of low socioeconomic status experience in the cancer care continuum 46, 
57. 
Conceptual Model to Inform Follow-up after a Positive Screening Mammogram 
Figure 5, adapted from the work of Zapka5, displays a conceptual model of the impact 
of both patient-level and healthcare system-level factors on diagnostic follow-up after a 
positive screening mammogram. The figure shows the general flow from screening to 
additional imaging if necessary and eventual resolution of the mammogram. The figure 
shows that multiple factors may influence the timeliness of follow-up after a positive 
screening mammogram.  
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Disparities in Diagnostic Follow-up after Positive Screening Mammogram 
 Though breast cancer mortality rates have declined over the past 10 years, mortality 
disparities exist for women of minority groups and those of low socioeconomic status (SES). 
Women of low-SES and minority, particularly African-American women, are less likely to 
receive screening mammography 34, present with more advanced disease, and are more likely 
to receive delayed care and experience increased wait time, than others after a positive 
mammogram 21-24, 35-50. Studies suggest extended time until follow-up varies by racial/ethnic 
group with African American women experiencing the longest delays when compared to White 
women 44, 49, 51. Additionally, persons living in rural areas have greater barriers (i.e. distance to 
facility, limited service availability) to receiving cancer care 52, 53. 
Untimely follow-up after a positive breast cancer screening mammogram may 
contribute to disparities in breast cancer outcomes and subsequently mortality. Specifically, 
follow-up times of 3-6 months have been associated with larger tumor size and reduced 
survival 14, 34, 54, 55. Below, we describe factors previously studied in the literature that may be 
important in diagnostic follow-up. 
Insurance 
Insurance status, particularly lack of insurance or enrollment in Medicaid, has been 
shown to be associated with poorer cancer outcomes 39, 40. In addition, multiple studies 
demonstrate that insurance status is a major determinant of cancer screening outcomes 58. 
Insurance status is an important indicator for screening because it directly corresponds to a 
woman’s ability to access certain types of care and to pay for health care. In studies of 
follow-up after positive screening mammogram women with private insurance were less 
likely to experience increased wait times beyond the CDC guidelines 25, 48.  
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Though the literature does not identify precise reasons for these disparities, the 
literature does point to two main issues that may contribute to these disparities. One is that 
facilities may represent what the literature terms vulnerable populations, or in other words, 
the facility serves a majority of uninsured patients or low-income patients such as patients 
with Medicaid 59. These facilities may have limited resources such as staff or adequate 
imaging machines to accommodate patients. The other idea is that though most insurance 
providers provide an annual screening mammogram as a covered service, what the insurance 
provides for follow up services may vary. Some insurance providers may require approval or 
may require that a patient use a certain physician. These sorts of requirements could possibly 
add to the time needed to follow-up a positive screening mammogram. 
In the following sections we briefly describe some common insurance categories. 
These insurance categories will be of interest in the study. 
Medicare 
Medicare is a national health insurance program for people ages 65 and older, people 
under 65 with specific disabilities, and those with End Stage Renal Disease. The Centers for 
Medicare & Medicaid Services runs Medicare, currently covering close to 50 million people 
in the United States. Medicare offers three parts depending on the desired coverage and 
needs. Part A covers inpatient hospital care, skilled nursing facilities, and critical access 
hospitals. Most people do not pay a monthly premium for Part A. Part B covers services 
outpatient care and doctor’s office services and supplies. Most beneficiaries pay a monthly 
premium for Part B. Medicare Prescription Drug coverage is provided through private 
insurance companies. Medicare beneficiaries pay a premium for these services, which may 
help defray the costs of prescription drugs.  Medicare Part B covers screening mammography 
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in full once every 12 months. Digital and film mammography are both covered 60. Women 40 
and over who have Medicare are covered for screening mammograms provided the facility 
and health care provider accept Medicare. Women between the ages of 35 and 39 can receive 
one baseline mammogram for comparison to future images once they become eligible for 
routine screening. Medicare does not cover MRI for screening purposes 60. Diagnostic 
mammography is covered where deemed medically necessary and women with part B must 
pay a deductible for diagnostic mammograms as well as 20% of the Medicare approved 
amount that a doctor can be paid for performing mammogram 60. Medicare offers a Part C 
plan or Medicare Advantage Plan that beneficiaries can buy into. This type of plan is offered 
and administered by a private insurance company. 
Medicaid 
Medicaid is a national health insurance program that provides free or reduced cost 
coverage for families, individuals, and children. Medicaid beneficiaries can include parents, 
the elderly, children, and adults with certain disabilities 61.  The Centers for Medicare & 
Medicaid Services monitors the Medicaid programs offered by each state. Coverage varies 
based on need. North Carolina Medicaid beneficiaries ages 40 and up can receive one 
screening mammogram annually. Beneficiaries ages 20 to 39 can receive one mammogram 
annually provided that she meets certain characteristics for a high-risk profile. These include 
documentation of positive BRCA mutation, personal history of ovarian cancer, previous 
atypical biopsy, or family history of breast cancer among a first-degree relative. Male 
beneficiaries are not covered for mammography screening.   
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National Breast and Cervical Cancer Early Detection Program (NBCCEDP) 
In order to reduce the breast cancer burden experienced by low-income women the 
CDC-funded National Breast and Cervical Cancer Early Detection Program (NBCCEDP) has 
provided cancer screening services, patient navigation assistance, and follow-up diagnostics 
and treatment to underserved women 11, 20. Women eligible for participation in North 
Carolina are between the ages of 40 and 64, have a household income less than 250% of the 
federal poverty level, and are uninsured or underinsured (not enrolled in Medicaid or 
Medicare Part B) 62. The program includes a patient navigation component to ensure 
adequate and timely access to services and follow-up if needed, which Medicaid does not 
offer to patients.  North Carolina offers the program to eligible women through health 
departments, community health centers, hospitals, and some physician offices. Currently 
more than 12,000 women participate in the NC program (10% of eligible North Carolinians), 
and many use NBCCEDP as their sole source for medical screening 63. This group of women 
represents a critical demographic that is often missing from other breast cancer studies as 
they do not qualify for Medicaid but are generally not able to afford private insurance 
coverage. It is also possible that this group of women may be misclassified as uninsured or 
‘other’ insurance. Most studies (unless they specifically use NBCCEDP data) will not have 
information on this group of women. 
Private insurance 
Traditional fee for service insurance is generally offered through place of 
employment (generally group plans) or it can be bought individually or provided by a parent 
or spouse. These types of plans generally cost more than other insurance types. 
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A Health Maintenance Organization (HMO) is a type of private insurance plan that 
generally provides coverage within a specified network of providers and medical facilities. 
The providers and facilities contract with the insurance provider for medical services. 
Services received outside of the network are generally not covered by the plan. Most 
members of HMOs pay a fixed fee and select a primary care physician.  
A Preferred Provider Organization (PPO) plan provides features found in both 
traditional private insurance plans and HMO plans. They often have premiums that are less 
than a traditional plan but may include co-insurance and/or co-pays that are due at the time of 
service.  
Other Factors Thought to Influence Follow-up after a Positive Screening Mammogram 
Breast density 
Breast density measures and classifies the composition of tissue within the breast. 
Specifically, it refers to the amounts fat and fibrous tissue that can be viewed in the breast via 
mammogram. A dense breast exhibits more fibrous tissue than fatty tissue. BIRADS 
classification measures tissue composition in the breast as viewed via mammography (Table 
4). Higher breast density has been found to be a risk factor for breast cancer 64-66. This 
phenomenon is due in part to the radiographic appearance of the highly dense breast. In a 
highly dense breast, tumors may be obstructed from view. Studies show that among women 
with highly dense breasts, mammographic sensitivity may be reduced 42. It may be harder to 
achieve follow-up for images of dense breasts as the increased density makes it more difficult 
for the radiologist to interpret the image. There is also some information to demonstrate that 
highly dense breast tissue may have increased amounts of stroma and epithelium. Stroma is 
connective tissue that provides support within the breast. Breast epithelium refers to the 
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tissues that provide the lining of the ducts. The majority of breast cancers will originate in the 
epithelial cells. There is some information to suggest that high breast density and the 
activation of the epithelial cells in the breast 67, 68. Additionally, studies suggest indeterminate 
results of screening mammography (not clearly positive or not clearly negative) and high 
breast density may lead to increased follow-up times 32. These factors, whether at the 
demographic or healthcare system level, may impact time to diagnostic follow-up after a 
positive screening mammogram. Figure 6 displays a comparison of the four levels of breast 
density as classified using the BIRADS system. 
Table 4. Summary of Breast Density Classification 
BIRADS Density 
Category 
Description 
1 Almost entirely fat 
2 Scattered fibrograndular densities 
3 Heterogeneously Dense 
4 Extremely Dense 
Age is another component that has been shown to influence breast density. Generally, 
breast cancer incidence increases with age 7.  Specifically, women over the age of 50 are 
more likely to be diagnosed with breast cancer when compared with women under the age of 
50. However, breast density decreases as women age. Because cancer incidence increases 
with age, screening recommendations for mammography are age-based, and age determines 
eligibility for some insurance programs (i.e. Medicare) we consider age to be an important 
covariate in these analyses. 
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Figure 6. Comparison of BI-RADS Assessment Categories for Breast Density 69 
Race 
African American women are more likely to be diagnosed with breast cancer at a 
younger age (pre-menopausal women ages 40-50) when compared to white women of the 
same age group.  Though white women have the highest incidence of breast cancer in the US, 
African American women have a higher mortality rate from breast cancer when compared to 
white women 51. Studies point to a multitude of reasons to explain this phenomenon. Some 
studies suggest that African American women may be more likely to have aggressive cancers 
(basal-like breast cancer). Other evidence suggests differences in lifestyle health behaviors 
such as diet, an increase in chronic diseases and comorbidities such as heart disease and 
diabetes, differences in health seeking behaviors such as delaying care, or decreased access 
to healthcare 70. 
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Socioeconomic status 
Socioeconomic factors such as education, income, and access to healthcare facilities, 
not only impact breast cancer diagnosis and treatment, but are also shown to impact follow-
up after a positive screening mammogram. Low-income and underinsured women present 
with more advanced stages of breast cancer 36, 39, 40 and have higher breast cancer mortality 
rates 35-38 and delayed diagnosis 71. Income may influence health-seeking behavior because of 
a patient’s ability or inability to pay for care. Higher socioeconomic status is associated with 
increased access to health care and increased access to resources that would facilitate health 
care access 39, 57. Studies show that women who understand their risk and the procedures 
required are more likely to seek care and comply with recommendations 47. 
Family history and previous breast biopsy 
 Women who have a family history of breast cancer, particularly a first degree relative 
such as a mother, sister, or daughter, are more likely to be diagnosed with breast cancer 7. 
The likelihood increases with more than one first-degree relative diagnosed with breast 
cancer. These associations point to a genetic component in breast cancer. Scientists have 
identified and studies have shown that two genes in particular are responsible for increased 
risk of breast cancer among women and among family members. Though having the genes 
BRCA1 and BRCA2 do not guarantee that a woman will develop breast cancer, expression 
of the gene appears to increase breast cancer risk. Women who have a family history of 
breast cancer may also be more aware of their risk of developing cancer and may be more 
likely to seek out breast cancer screening. 
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Facility-level factors 
 Facilities performing mammography can exhibit a multitude of variations. Women 
can receive breast imaging services at facilities as varied as hospitals, outpatient clinics, 
breast centers, mobile mammography units, physician practices, and health departments. 
Additionally, services offered by each facility and protocols followed may vary. For instance 
some facilities have radiologists on sight to read and interpret images and provide immediate 
referral while some facilities send images to radiologists at other locations 23. At some 
facilities the images are read while the woman waits and at others the images are read in 
batches. This may require subsequent visits which could be time consuming, financially 
taxing, or impede follow-up.  The type of equipment and technology used at facility may also 
vary. Some facilities only use film while some only use digital imaging. Studies have shown 
variability in facility in screening outcomes particularly among facilities that serve 
vulnerable populations 72.  
Imaging modality  
Imaging modality refers to the medium in which the mammogram image is captured. 
A film mammogram indicates the image of the x-ray is viewed and stored on film. For digital 
images, the image of the x-ray is converted electronically. Overall, it appears that detection 
of breast cancer is similar for the majority of women 73 however; it has been shown that in 
some cases digital mammography may detect some cancers not identified on film 74. Among 
younger women with high breast density digital mammography may perform better in cancer 
detection 75.  Additional benefits of digital mammography may include: enhanced image 
quality, digital storage and transfer, decreased wait time for processing and review, computer 
assisted interpretation.  
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Digital mammography is more expensive than film mammography. Many practices 
and mammogram facilities are switching to digital mammography. In some areas, 
particularly rural areas, digital mammography may not be available to patients. Digital 
mammography may also perform better for women less than 50 years of age and pre-
menopausal women 74. Figure 7 shows a mammogram image of the breast. The mammogram 
on the left side is film mammography. The image on the right is digital mammography. This 
image appears clearer when compared to the image taken using film mammography.  
	
Figure 7. Visual Comparison of Digital and Film Mammography 75 
Patient residence 
 Where a patient lives influences their access to healthcare facilities and services and 
will thus influence healthcare outcomes. Geographic factors have also have been shown to 
play an important role in access to cancer screening both in terms of access to facilities and 
the distance a patient must travel to receive cancer care 52, 53. Patients living in rural areas 
may have limited access to healthcare including breast cancer care facilities 53. This could be 
due to a limited number of facilities near the patient or barriers to access facilities such as 
travel distance. In a study of treatment of breast cancer patients, women living longer 
distances from healthcare centers were less likely to receive certain treatments 53. 
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Summary of the Literature  
A summary of factors contributing to diagnostic follow-up time used previously in 
the literature is presented in Table 5. This summary represents the most common covariates 
included in adjustment sets of the models. The most common variables adjusted for are: age, 
race/ethnicity, history of breast cancer, socioeconomic status, and insurance. Table 6 
summarizes key terms and definitions presented in the literature review that are important for 
this study. 
  
 27 
Table 5. Adjustment Variables used in the Literature on Diagnostic Delay after a Positive 
Mammogram 
Author (Year) Adjustment Variables 
Battaglia 
(2006)25 
age, race/ethnicity, insurance, reason 
for referral, source of referral 
Bobo (2004)56 race/ethnicity, education, history of 
breast cancer, program (state), 
sampling weights 
Chang (1996)22 age, race/ethnicity, family history of 
brca, presence of palpable mass, 
income, screening mammography 
interpretation 
Clark (2009)76 insurance, regular provider, site, 
SES 
Decker (2004)23 age, open biopsy, core biopsy, 
family history of breast cancer, 
screening visit, abnormal CBE, 
abnormal mammogram, final dx, avg 
number of dx procedures excluding 
surgical consultation. 
Elmore (2005)21 income, age, insurance, 
Gorin (2006)44 stage, SES, census tract, 
comorbidities, urban residence, year 
of dx, HMO membership 
Gwyn (2004)27 age, family history, marital status, 
poverty index, method of detection, 
insurance status 
Haas (2000)77 age, race, family history, education, 
insurance status, worry, radiographic 
result of mammogram, site of care 
Halpern (2008)40 age, income, education based on 
postal code, US census region of 
residence, year of dx, facility type 
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Table 6. Summary of Key Terms in this Study of Time Until Diagnostic Follow-up after a 
Positive Screening Mammogram 
Term Definition 
Benign Screening Result Screening mammographic examination with 
a negative interpretation or BIRADS 
categories 1, 2, or 3 with no follow-up 
recommendation 
Breast Density “Describes the relative amount of different 
tissues present in the breast. A dense breast 
has less fat than glandular and connective 
tissue. Mammogram films of breasts with 
higher density are harder to read and 
interpret than those of less dense breasts.” ‡ 
Diagnostic Mammogram “X-ray of the breasts used to check for 
breast cancer after a lump or other sign or 
symptom of breast cancer has been found.” 
‡ 
Diagnostic Follow-up Time in days after a positive screening 
mammogram result until first follow-up 
procedure (i.e. additional breast imaging or 
biopsy) 
Diagnostic Resolution Time in days from the initial positive 
screening mammogram result until the date 
of the last follow-up procedure (i.e. 
additional breast imaging or biopsy) before 
a cancer diagnosis or benign pathology 
result. 
Diagnostic Follow-up Pathway Series of diagnostic tests performed after a 
positive screening mammogram result 
Imaging Modality Mammograms are performed either on film 
or digitally  
Positive Screening Result Screening mammographic examination with 
a positive interpretation or BIRADS 
categories 0, 4, 5 or 3 with follow-up 
recommendation 
Screening Mammogram Screening mammography is performed for 
women without breast symptoms, some 
studies include women with symptoms † 
†From Rosenberg 2006 78 
‡ From NCI Dictionary of Cancer Terms 79 
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CHAPTER 2: SPECIFIC AIMS 
The advantages of early detection gained through screening may be diminished if 
positive mammogram test results do not lead to timely diagnosis and treatment. Current CDC 
guidelines recommend women receive diagnostic follow-up and begin treatment if necessary 
within 60 days of a positive screening mammogram result. Despite this, disparities in both 
diagnostic follow-up time (defined as the time from a positive screening result to the first 
diagnostic exam/procedure) and diagnostic resolution time (defined as the time from a 
positive screening result to the last work-up procedure leading to breast cancer diagnosis or 
benign result) continue to exist. 
Minorities, those of low socioeconomic status, those living in rural areas, Medicaid 
recipients, and the uninsured are more likely to experience increased wait time for diagnostic 
resolution of a positive screening mammogram result. Understanding disparities in diagnostic 
follow-up and resolution among underserved women is crucial since this group of women 
present with advanced stages of breast cancer and have higher breast cancer mortality rates 
compared to insured non-low income women. 
 The dissertation research focuses on insurance status to better understand disparities 
in resolution of breast cancer screening. Specifically, we examine the association between 
insurance status and time until diagnostic follow-up after a positive screening mammogram 
result using data from the Carolina Mammography Registry (CMR). The data include patient 
demographics, comprehensive patient risk factor data (breast density, family history, 
menopausal status), data on the imaging exam performed, reason for the breast imaging visit, 
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the radiologists’ assessment of the imaging exam and recommendation for follow-up, and 
pathologic cancer outcomes from the North Carolina Central Cancer Registry and from 
abstracted pathology reports. We accomplished the overall objective of the study with the 
following specific aims: 
1. Assess the relationship between insurance status and initial diagnostic follow-up after 
a positive screening mammogram in a large, racially diverse population. 
Hypothesis: Among women with a positive screening mammogram result, women reporting 
Medicaid and the uninsured will experience an increased time to diagnostic work up and 
diagnostic resolution when compared with women with private insurance. 
2. Compare the diagnostic follow-up pathways observed after a positive screening 
mammogram result by insurance status. 
Hypothesis: Among women with a positive screening mammogram, the number and type of 
subsequent imaging/procedures does not differ by insurance status. 
2a. Examine differences in the diagnostic follow-up pathways by insurance status and 
assessed the association between insurance status and receipt of biopsy 
Hypothesis: Among women with a positive screening mammogram, women reporting private 
insurance will be more likely to experience a clinical follow-up pathway that includes biopsy. 
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CHAPTER 3: METHODS 
Overview 
A retrospective cohort design was used to examine the association between insurance 
status and time until diagnostic follow-up after a positive screening mammogram result. 
Results from this study assessed whether the amount of time from a positive screening 
mammogram until diagnostic follow-up varied by insurance status as well as enumerated the 
different clinical pathways women may experience to resolve a positive screening result. We 
used data from the Carolina Mammography Registry from the years 1995-2010 for women 
who were at least 40 years of age, and had a positive screening mammogram result.  
CMR has collected prospective data from participating mammography facilities in 
North Carolina since 1994. The CMR data include information on sociodemographic 
characteristics of women, reason for the breast imaging visit, breast cancer risk factors, and 
result of the imaging exam performed, the screening findings, and management 
recommendations of the radiologist. CMR data also include patient insurance status at the 
time of the mammogram as well as breast cancer outcomes and pathology results from the 
North Carolina Central Cancer Registry.  
Data Source: Carolina Mammography Registry 
Studying the association between insurance status and time until diagnostic follow-up 
requires accurate information on breast imaging. The CMR, a National Institutes of Health 
(NIH) funded, state-based population-based registry collects patient, radiologist and 
associated breast cancer-related outcomes among women screened for breast cancer in NC 80. 
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CMR provides quality improvement reports to participating facilities to help with reporting 
requirements of the Mammography Quality and Standards Act (MQSA) 81. CMR is also an 
active member of the Breast Cancer Surveillance Consortium (BCSC), a national research 
program that pools data from six mammography registries in the US 82. CMR data has been 
used widely to assess the utility and performance of mammographic screening for breast 
cancer research 64, 78, 83-94.  
	
http://www.cmr.unc.edu  
Figure 8. Breast Cancer Surveillance Sites 95 
Data in CMR come from 38 breast imaging practices comprising 80 facilities across 
the state of North Carolina. CMR receives pathology data collected from mammography 
facilities in 24 of 100 North Carolina counties. Each CMR participating facility collects 
standardized data using a standard form and reports this data to CMR. CMR also abstracts 
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pathology information from hospital pathology reports that are collected through the 
Lineberger Comprehensive Cancer Center Rapid Case Ascertainment (RCA) program. The 
RCA program provides accelerated identification of cancer patients throughout the state. 
	
Figure 9. Imaging Facility Coverage for the Carolina Mammography Registry by North 
Carolina County 
Created by the CMR Project Manager http://www.cmr.unc.edu  
The North Carolina Central Cancer Registry (NC CCR) collects cancer case reports, 
along with diagnostic and initial treatment data for all cancer cases diagnosed among North 
Carolina residents. The data collected from imaging facilities is routinely updated and linked 
with state mortality data as well as data from the North Carolina Central Cancer Registry 
(NC CCR) for determination of cancer-related outcomes. Information from the women and 
the radiologist interpreting the screening mammogram has been recorded and linked to 
associated cancer outcomes. CMR data is linked annually with NC CCR and pathology data 
to ascertain cancer status, stage, and related information. CMR includes over 15 years of 
linked data making it relatively easy and cost efficient to enumerate the entire cohort of 
women receiving screening mammograms and to follow these women retrospectively as 
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opposed to recruiting and enrolling a new sample of women to follow prospectively. Unlike 
other data sources, (i.e. Cancer Registry, Medicare, or Medicaid claims data alone) CMR 
contains information on the radiologists’ interpretation of the screening mammogram as well 
as woman-level risk factor information such as breast density. Other data sources may 
contain only a medical billing code to indicate that a mammogram was completed making it 
necessary to collect and abstract medical records to obtain the screening mammogram test 
result.  
Data Acquisition and Dataset Creation  
CMR data from 1995-2009 were collected under a waiver of consent as approved by 
the Institutional Review Board (IRB) at The University of North Carolina at Chapel Hill 
(UNC). CMR data from 2010 to the present were collected with an opt-out option. This 
ancillary studied has received approval from the UNC IRB (IRB #11-1606).  
Source Population  
Data describing the source population, before application of study inclusion and 
exclusion criteria, are presented in Table 7. The left-hand side of Table 7 displays some 
general characteristics of screening mammograms in the CMR data for the years 1995-2010. 
Currently, the CMR contains patient and radiologist data from 1995-2010, with cancer 
registry data and pathology-associated outcomes through 2011. The right hand side of Table 
7 displays demographic information for women with positive screening mammograms in the 
CMR data. The numbers in the table represent exams, not individual women.  
Of all screening mammograms in the data for the study years screening mammograms 
represent approximately 9%. The population is fairly young with approximately 23% of 
women between the ages 50-59 and 20% between the ages 40-49. The majority of the 
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population is White followed by nearly 18% of the population reporting their race as Black 
or African-American. Only 10% have less than a high school education. The majority report 
having private insurance followed by Medicare (16%).  
Table 7. Demographic Characteristics of CMR Study Population (1995-2010) 
Characteristic  All Screening 
Mammograms 
n=1,853,944 
n (%) 
Positive Screening 
Mammogram Result 
n=172,787 
n (%) 
Age   
    18-39 113,948 (6.1) 11,313 (6.5) 
    40-49 375,991 (20.3) 42,110 (24.4) 
    50-59 426,864 (23.0) 38,454 (22.2) 
    60-69 314,196 (16.9) 29,534 (17.1) 
    70+ 270,714 (14.6) 51,376 (29.7) 
Race   
    Black 326,440 (17.6) 42,437 (24.6) 
    White 1,357,379 (73.0) 111,813 (64.7) 
    Other 21,810 (1.2) 1,941 (1.1) 
    Missing 148,315 (8.0) 16,596 (9.6) 
Educational Status   
    <High School 185,103 (10.0) 17,201 (10.0) 
    High 
School/GED 
381,912 (20.6) 35,886 (20.8) 
    Some college 296,631 (16.0) 27,298 (15.8) 
    College 
Graduate 
341,417 (18.4) 31,065 (18.0) 
    Missing 648,881 (35.0) 61,337 (35.5) 
Insurance    
    Medicare 303,064 (16.3) 27,039 (15.6) 
    Medicaid 72,303 (3.9) 7,532 (4.4) 
    BCCCP 26,118 (1.4) 2,716 (1.6) 
    Private 809,936 (43.4) 82,971 (48.0) 
    Missing  642,523 (34.7) 52,529 (30.4) 
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Study Population 
 This study included data on breast imaging examination and pathology result through 
2010 and cancer diagnosis through 2011. The study population consisted of female North 
Carolina residents included in CMR from 1995-2010 who were at least 40 years of age, had a 
positive screening mammogram result and who did not have a personal history of breast 
cancer. Women less than 40 years of age were excluded since they have not historically been 
recommended for routine mammography screening 4. There were no exclusions based on 
race, ethnicity, or geographic region. Only women were included in the study as male breast 
cancer is clinically considered a separate pathology. Also, men are not currently 
recommended to receive routine screening mammography for breast cancer prevention 1.  
Facility Exclusions 
 Exclusions at the facility level were implemented for this study. We excluded the first 
two years of data for each facility, a total of about 11,000 exams. Facilities included in the 
CMR standard facility exclusion list were excluded, a total of 6 facilities. Facilities that do 
not use the CMDS system to collect data were excluded from these analyses, a total of 13 
facilities. CMDS is CMR’s custom radiology information software for data capture, 
reporting, tracking, and monitoring breast imaging procedures. The software complies with 
the Mammography Quality Standards Act Regulations (MQSA) reporting requirements 81 
and the breast density notification law (H.B. 467). It facilitates tracking and follow-up of 
positive assessments and outstanding patients and generates letters for patient reminders, 
mammography reports, and pathology reports as well as creates reports for mammography 
quality control and medical outcomes audit. For facilities that ended participation in CMR 
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during the study period we required that a woman’s first positive screening mammogram 
occur at least 365 days before the end date of facility participation.  
Definition of Screening Mammography in the CMR 
Study eligibility is limited to women undergoing a screening mammogram and only 
women with a positive screening mammogram were included in the study population. At the 
time of the mammogram the radiologist recorded whether the examination was a screening or 
diagnostic mammogram. Using BCSC definitions, a screening mammogram is defined as 
routine bi-lateral views of the breast among women without breast symptoms such as pain or 
lump 12. The radiologist reports information on the type of mammogram performed by 
answering the following questions: “What is the reason for this visit?” and “What exams 
were performed at this visit?” The response options are: Asymptomatic (screening 
mammogram); Symptomatic, problem solving, diagnostic follow-up; Continued follow-up 
following abnormal mammography; Short-term follow-up (mostly 6 month follow-up; 
Biopsy; Other. We considered a response of “asymptomatic (screening mammogram)” and 
“Screening 2-view mammogram” respectively, as indication of screening mammography. 
Identification of a Positive Screening Mammogram in the CMR 
A positive screening mammogram was defined using BCSC definitions 10. To be 
considered positive the radiologist had to assign the screening mammogram a Breast Imaging 
Reporting and Data System (BI-RADS) assessment of 0 (needs additional imaging), 4 
(suspicious abnormality), 5 (highly suggestive of malignancy), or 3 (probably benign 
finding) with the radiologist’s recommendation for immediate follow-up (surgical consult, 
biopsy, or fine needle aspiration) 16. These groupings are presented in Table 8. Among 
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women with more than one positive screening mammogram, one positive screen was 
randomly selected.  
Table 8. Categorization of Screening Mammogram Result Using the Breast Imaging and 
Reporting Data System (BIRADS) 
BIRADS 
Category 
Assessment Screening 
Mammogram 
Result 
0 Incomplete Needs additional 
Imaging Evaluation 
Positive 
1 Negative Negative 
2 Benign 
3 Probably Benign without 
recommendation for 
immediate follow-up 
Negative 
3 Probably Benign with 
recommendation for 
immediate follow-up 
Positive 
4 Suspicious Positive 
5 Highly Suspicious of 
Malignancy 
6 Known Biopsy Proven 
Malignancy 
Adapted from Eberl et al 2006 16 
Exposure Assessment: Insurance Status 
The main exposure is insurance status. In the CMR data, the type of insurance used to 
pay for the screening mammogram is collected from patients in the mammography facilities 
at the time of the breast imaging exam. The CMR insurance question asks: “Is your insurance 
paying for this visit? - If yes please check which insurance.” The options are: Medicare, 
Medicaid, BCCCP, Private, and Other. The other box provides a space where women can 
write in their selection. Women are allowed to select more than one option on the form. The 
National Breast and Cervical Cancer Early Detection Program or NBCCEDP (referred to 
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using the acronym BCCCP in North Carolina) is a program that provides free breast and 
cervical cancer screening to women who are uninsured 62.  
In CMR insurance is coded as separate dichotomous variables. For the purposes of 
this study we created a new categorical variable using the existing insurance variables to 
accommodate women who reported with multiple insurance providers by checking more than 
one box on the form. These categories were:  
Medicare Only: Women in this category selected Medicare as the sole source of 
insurance paying for the screening mammogram. 
Medicare & Private: Women in this category selected Medicare and either Managed 
Care or Private as the sources paying for the screening mammogram. These women selected 
no other insurance categories. 
Medicaid Only:  Women in this category selected Medicaid as the sole source of 
insurance paying for the screening mammogram. These women selected no other insurance 
categories. 
Medicare & Medicaid: Women in this category selected Medicare and Medicaid as 
the sources of insurance paying for the screening mammogram. These women selected no 
other insurance categories. 
Private: Women in this category selected either private insurance or Managed Care as 
the sources of insurance paying for the screening mammogram. These women selected no 
other insurance categories. 
NBCCEDP: Women in this category selected BCCCP and Other. No women in the 
study sample selected only BCCCP.  
No Insurance: Women who selected the ‘No’ option were included in this category. 
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Women who did not select a box for this question were categorized as having an unknown 
insurance status. Table 9 displays the CMR variables used in exposure assessment. 
Table 9. Variables Used in Exposure Assessment 
CMR 
Variable 
Name  
Description Value 
BCCCP Insurance=BCCCP? Y=Yes 
N=No 
INSHMO Is the patient’s 
insurance an HMO? 
Y=Yes 
N=No 
MEDICAD Covered by 
Medicaid? 
Y=Yes 
N=No 
MEDICAR Covered by 
Medicare? 
Y=Yes 
N=No 
NOINS Not covered by 
insurance? 
Y=Yes 
N=No 
OTHINS Covered by other? Y=Yes 
N=No 
PRIINS Private? Y=Yes 
N=No 
Outcome Assessment: Time until Initial Diagnostic Follow-up 
The primary outcome of interest was time until initial diagnostic follow-up defined 
as the time in days from the initial positive screening mammogram result until the date of the 
first/initial follow-up procedure (i.e. additional breast imaging or biopsy) before a cancer 
diagnosis or benign pathology result. After the examination the radiologist reports findings 
from the screening mammogram, lists other imaging studies needed to resolve the screening 
assessment if the result is positive, and provides recommendations for follow-up.  
An examination for diagnostic follow-up (visit made after the date of the initial 
positive screening mammogram) may include a combination of procedures such as 
diagnostic mammography, ultrasound, MRI, or confirmatory biopsy. Definitions of these 
procedures are listed in Table 3. These procedures were identified using variables found in 
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the CMR data. (Table 10) CMR variables and their associated dates were used to calculate 
follow-up time in days after a positive screening mammogram. 
Statistical Analyses 
We performed exploratory analysis of the data for distributions among each covariate. 
For continuous variables we studied graphical representations and for categorical variables 
we created tabular representations to view the distributions of each variable. Error checks for 
missing or implausible values were performed. In the event that the date for a follow-up 
examination (such as a confirmatory biopsy), occurred before the screening mammogram 
that value was re-coded as missing.  
 We provided descriptive statistics of the study population and described the time in 
days from a positive screening mammogram until initial follow-up for the total population 
and by insurance status. We summarized screening mammography use, and described the 
series of examinations and procedures (diagnostic follow-up pathways) the patient 
experienced to follow-up a positive screening mammography result. All p values were two-
sided and a value of p<0.05 was considered statistically significant. Statistical analyses were 
performed using SAS Software version. 9.3 96. 
Covariate Adjustment 
Assessment of confounding 
 Covariate selection was based on the Directed Acyclic Graph (DAG) as informed by 
the extant literature 97. Figure 10 displays the DAG of the relationships among insurance status, 
potential covariates of interest, and time until diagnostic follow-up after a positive screening 
mammogram. To determine the best model for predicting the relationship between insurance 
status and diagnostic follow-up, we constructed a conceptual model and DAG and assessed 
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explanatory variables determined by the literature to impact time until diagnostic follow-up 
after a positive screening mammogram 25, 98, 99. In the DAG (Figure 10) the variables Breast 
Density, Imaging Modality and Facility are colliders. Adjusting on these variables could 
potentially be a source of confounding and selection bias when assessing the effect of insurance 
status on time until diagnostic follow-up. This would occur if the association of insurance 
status and time until diagnostic follow-up changes when adjusting for the colliders 98. To assess 
the extent of this phenomenon we ran multiple models including and excluding these variables. 
Selected variables were examined using likelihood ratio tests 98. 
Based on our interpretation of the directed acyclic graph (DAG) the following 
variables were considered as potential confounders in the association between insurance 
status and time until diagnostic follow-up following a positive screening mammogram result: 
age, race, facility, imaging modality, and breast density. For comparison with prior studies, 
we also considered variables commonly adjusted for in the literature. These variables 
included: Age, Race, Education, Family history of breast cancer, and Patient residence 
(Previously presented in Table 5). Urban/Rural patient residence, facility type, and distance 
to nearest facility were not found to be statistically significant predictors of the outcome and 
were not included in the final adjusted models. The following covariates were included in the 
adjusted models: age, race, education, breast density, and family history of breast cancer. 
Covariates  
Covariate information is obtained by CMR at the time of the examination using a 
standard intake form created by CMR. Covariates of interest to assess the association of 
insurance status and time until diagnostic follow-up after a positive screening mammogram 
are summarized in Table 10. The patient reported demographic information at the time of the 
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mammogram using a standard patient questionnaire provided by CMR. These variables 
included:  
• Age at time of positive screening mammogram is a continuous variable 
calculated using patient reported date of birth;  
• Race (Black, White, Asian, Hispanic, American Indian, Other); and  
• Education (Less than High School Diploma, High School Graduate or 
Equivalent, Some College, College Graduate).  
Other variables were also assessed for inclusion in the model. Urban/Rural residence 
of the patient is based on patient-provided address at the time of service. A separate measure 
of distance to nearest radiology facility used the geocoded patient address to calculate 
continuous drive time in minutes to the nearest radiology facility for each patient. 
Information about breast density was reported at the time of the positive screening 
mammogram by the radiologist performing the mammogram using BI-RADS breast density 
classification on the standard form provided by CMR. Facility type at the time of breast 
imaging was categorized as either Hospital, Radiology private office, Comprehensive cancer 
center, Hospital outpatient center, OB/GYN office, Primary care office, Mobile unit, 
Multispecialty clinic. 
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Figure 10. Directed Acyclic Graph (DAG) of the Relationships among Insurance Status, 
Diagnostic Follow-up, and Covariates 
 52 
 Table 10. Measured Confounders Included in the Model 
CMR Variable 
Name  
Description CMR Values Notes 
AGE Age, 
continuous 
 Age at time of screening 
mammogram is calculated 
by CMR using date of 
birth. 
DENSE Parenchymal 
Breast Density 
1=ED  
2=HD 
3=SF 
4=EF 
BIRADS reporting: 
Extremely Dense 
Heterogeneously Dense 
Scattered Fibrodensities 
Entirely Fat 
EDUCAT Level of 
Education 
1=less than HS 
2=Some HS 
3=HS Grad 
4=Some College 
5=College Grad 
6=Grad School 
 
FACILITY 
 
 Hospital, Radiology 
private office, 
Comprehensive 
cancer center, 
Hospital outpatient 
center, OB/GYN 
office, Primary care 
office, Mobile unit, 
Multispecialty clinic. 
Practice location where 
the screening 
mammogram was 
performed. 
URBAN Patient lives in 
urban area? 
0=Rural 
1=Urban 
CMR includes an 
urban/rural indicator 
which is calculated using 
patient provided address 
at the time of 
mammogram 
DIGITALMAMMO Was digital 
mammography 
used? 
Y=Yes 
N=No 
 
RACE Race 1=Black 
2=White 
3=Asian 
4=Hispanic 
5=Indian 
6=Other 
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Methods for Aim 1: Assess the relationship between insurance status and time until 
diagnostic follow-up after a positive screening mammogram among a large, racially 
diverse population.  
 At the completion of aim 1, we will have an estimate of the association of insurance 
status on time until diagnostic follow-up after a positive screening mammogram. These 
estimates for each insurance status will help in the determination of whether insurance status 
predicts time until diagnostic follow-up after a positive screening mammogram by modeling 
the average time to follow-up.  
 To determine the best model for predicting the relationship between insurance status 
and diagnostic follow-up, we evaluated confounding using the covariates that were 
determined by the Directed Acyclic Graph (DAG) 98, 100 to impact time until diagnostic 
follow-up after a positive screening mammogram (Presented previously in Figure 10) 25, 99.    
Aim 1: Time-to-event Analysis 
 Any time before a positive screening result that a woman was included in the CMR 
data was not included in these analyses. Therefore the origin for time-to-event analysis is the 
date of the first positive screening mammogram result. When diagnostic follow-up of a 
positive mammogram occurred, the event had to include the date of follow-up so that the 
time in days from the positive screening mammogram to the follow-up examination could be 
calculated. Women were followed until a follow-up examination occurred or until 365 days 
after the positive screening mammogram. Hence, women were administratively censored at 
365 days after positive screening mammogram. Since censoring of women is expected, either 
through administrative censoring or loss to follow-up we computed median survival times 98. 
It is also expected that the distribution of time to follow-up after a positive screening 
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mammogram will not follow a normal distribution and will be skewed so a median is a 
statistically more appropriate option for presenting time until follow-up. We constructed 
survival curves using the Kaplan Meier estimator to show stratification on diagnostic follow-
up time by insurance status among women who are censored using the information from 
those who remain at risk 101.  
Model Description and Parameters for Calculation of Hazard Ratios 
 To assess the association between insurance status and time until diagnostic follow-
up after a positive screening mammogram we used Cox proportional hazards to estimate 
hazard ratios (HR) and 95% confidence intervals 102. The referent insurance group for ages 
64 and under was private insurance. For ages and over the referent category was changed to 
Medicare and Private because it was the most populous insurance group among the age 
category. The Cox Proportional hazards model is specified as:  
h1(t) = h0(t)*exp (βX + γZ) 
where: 
h0(t) = the reference hazard function for observations with X=Z=0 
β=the log hazard ratio for 1 unit change in exposure X while holding the covariate 
vector (Z) constant at any level 
γ= vectors of log hazard ratios for unit changes in the components of Z holding the 
exposure and other components of Z constant at any level 
X=exposure 
The Cox proportional hazards model does not estimate an intercept, so there is no coefficient 
for that. The reference hazard function is essentially the intercept. So it follows that the 
formula to calculate the hazard ratio (HR) can be written as:  
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HR = h1(t) / h0(t) 
When we add covariates to the model, exp (βx) is the HR for a unit difference in x holding 
the covariate constant at any level. h(t) is the underlying hazard function (which is not 
necessarily specified) 
– Exp (X1 β1) is sometimes referred to as the relative hazard function as it is used 
to estimate the relative hazard or hazard ratio. 
– We exponentiate the β estimates to obtain the hazard ratio of the exposed rate 
to the unexposed rate. 
– Proportional hazards regression: h(t|X) = h(t) exp (X1 β1 + ….+ Xp βp)  
Proportional Hazards Assessment 
We assessed proportional hazards by graphing the log of the cumulative hazards [log 
H(t)] against t for insurance. If the proportional hazard assumption is met these lines should 
be parallel indicating a constant ratio over time. If the proportional hazards assumption is not 
met, Cox does allow the model specification to accommodate non-proportional hazards 102 
.The method of graphing the log(-log(survival) versus log(time) doesn't work well for our 
categorical variable (insurance) because there are >2 levels making it hard to see lines, but 
we can tell that they do cross and so proportional hazards assumption is not met.  
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Figure 11. Graph of the Log(-Log(Survival) Versus Log(Time) 
 
We can then use the SAS procedure phreg 96 to execute the test statement to test all 
the time dependent covariates at once to compare the smaller model without any covariates to 
the larger model that includes all the time dependent covariates. If any of the time dependent 
covariates are significant then those predictors are not proportional. The only covariate that 
was significant was facility type.  
If the proportional hazards assumption is not met we must stratify by the levels of 
categorical variable for which the proportionality assumption fails. In this approach a 
separate baseline hazard is assumed for the members of each stratum but all the data are still 
used to obtain the parameter estimates 102. After collapsing categories of facility proportional 
hazards assumption is met. The new categories are: hospital, all radiology offices, & Primary 
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care. Primary care includes primary care office, OB/GYN, multispecialty clinic, mobile van. 
The proportional hazards assumption was met indicating a constant ratio over time 102. 
Linear Hypotheses Testing Results for Proportional Hazards 
  
Label (without facility type) 
Wald 
Chi-Square 
DF Pr > ChiSq 
  
Proportionality_test 
4.7075 3 0.1945 
Kaplan Meier Estimates of the Survival Function 
The Kaplan Meier estimate computes probabilities of occurrence of event at a certain 
point in time 102. We multiply these successive probabilities by any earlier computed 
probabilities to get the final estimate. For each time interval, survival probability is 
calculated as the number of subjects surviving divided by the number of patients at risk. 
Subjects who have died, dropped out, or moved out are not counted as at risk and are not 
counted in the denominator. The Kaplan Meier enables us to use information from 
observations that are censored up until the time they are censored 103. Looking at the Kaplan 
Meier plot we see that beyond 12 days half of the population is expected to have received 
initial follow-up and beyond 23 days 75% of the population has received initial follow-up. 
If we suspect the survival function is not the same among some groups of insurance 
status we can use non-parametric methods to test for equality of the survival function among 
groups using the log rank test to test the null hypothesis that there is no difference in survival 
among the groups, which will give us a chi-square and a p-value. The chi square is 94.57 and 
the p-value is <.01 which supports the idea that survival differs between insurance status. The 
log-rank test does not allow us to test the effect of other independent variables so we use Cox 
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proportional hazard model to test the effect of independent variables on survival times of 
different groups. 
	
Figure 12. Plot of the Cumulative Hazard Function for the Study Cohort 
The cumulative hazard function sums hazards over time because it integrates the 
hazard function over a time period. The cumulative hazard function and the survivor function 
have a monotonic relationship; when the survival function is at its maximum at the beginning 
of the analysis time period, the cumulative hazard function is at its minimum. As time 
progresses the survival function proceeds towards its minimum and vice versa for the 
cumulative hazard. We see a sharp rise in the cumulative hazard at the start of time, which 
reflects the larger hazard rate during this time period. 
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Aim 1: Multivariable logistic regression predicting time to follow-up greater than 60 
days 
We also used multivariable logistic regression to estimate odds ratios and 95% 
confidence intervals for time to initial follow-up beyond 60 days based on the CDC 
guidelines. In both sets of models, the referent group for women younger than 65 years was 
Private insurance alone. The referent group in the models for ages 65 and over was Medicare 
& Private; among the older women, it was the most populous category for this age group. 
Aim 2. Determine whether diagnostic follow-up pathways observed after a positive 
screening mammogram result differ by insurance status. 
In aim 2 we assessed the series of clinical procedures (diagnostic follow-up 
pathways) a woman experienced to resolve a positive screening mammogram result. These 
pathways may include a single diagnostic mammogram or may be much more complicated 
and include multiple diagnostic imaging exams and biopsies. As insurance providers may 
cover varying services or require approvals before procedures can be administered, we were 
interested in knowing if the pathway is influenced by insurance status. Additionally we were 
interested in identifying pathways to resolution as a woman’s pathway may give increased 
insight into the time between a positive screening mammogram result and diagnostic follow-
up. For common diagnostic pathways, we compared the distribution for each insurance 
status. We then tested for differences by insurance status using a Chi-square test (Χ2).  
For comparison with the work on pathways conducted by Hubbard and colleagues 33 
we categorized the series of examinations for each woman by insurance status and examined 
the most common diagnostic follow-up pathways. We calculated the median time for 
diagnostic follow-up by pathway.  
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Aim 2a. Association between insurance status and a pathway including biopsy. 
We used multivariable logistic regression to estimate odds ratios (OR) and 95% 
confidence intervals (CI) for the association between insurance and a pathway including 
biopsy for two age groups of women: under 65 years of age and 65 years and over. The 
referent group for women younger than 65 years of age was Private insurance. The referent 
group for ages 65 years and over was Medicare & Private; it was the most populous category 
for this age group. 
Missing Data: Sensitivity Analysis using Simple Insurance Imputation 
 Insurance statusis not collected by all facilities participating in CMR. Approximately 
32% of positive screening examinations were missing insurance status. Possible reasons for 
the missingness in these covariates could be that the women are not provided with these 
questions on the CMR intake forms and this information is subsequently missing in the CMR 
data system. This would be happening at a facility level and gives support for inclusion of 
facility in the models. For the purposes of the analysis we only include imaging exams where 
insurance status is not missing. 
We conducted a sensitivity analysis by assigning missing insurance status at the time 
of the positive mammogram based on a previous report of insurance status in the CMR data. 
That is, if the woman was found in the CMR data at a date earlier than her positive 
mammogram included in the study and reported an insurance status, that insurance status was 
used in the present study. This method reduced missing insurance status by 2 percentage 
points. Those excluded from the complete case analysis for missing insurance status were 
younger (20% were 65 or older) and most have missing educational status (75%) and are 
more likely to have missing race/ethnicity. Since these covariates normally used to complete 
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more complex forms of imputation are largely missing among this group, multivariate 
imputation was not an option for this study. 
Sensitivity Analysis: Impact of BCCCP Program 
 BCCCP is a program that women can apply to for free breast and cervical cancer 
screening. For breast cancer screening women can receive follow-up imaging if needed. The 
committee agrees that BCCCP is not technically an insurance however the women who 
receive BCCCP are different than the uninsured women in that they are receiving screening, 
follow-up and have access to a navigator from the program who will help them schedule 
visits. This is in an effort to stay within the CDC guidelines of 60 days for follow-up after a 
positive screening mammogram. There were less than 1,200 women reporting BCCCP in the 
study cohort. Ultimately we excluded women reporting participation in BCCCP from the 
analyses. We found that it was unclear what insurance category to best group them with, 
especially since all in the study population indicated some other insurance category along 
with BCCCP. No one in the study population reported BCCCP only, which lead us to believe 
that BCCCP may not really be acting as a stand-alone insurance category. We do believe that 
it is worth analyzing these women separately but not in the current study. 
Sensitivity Analysis: BIRADS 3  
As previously discussed the Breast Imaging and Reporting Data System (BIRADS) 
was developed to standardize the reporting of mammography results. Estimates suggest that 
between 1 and 12% of mammograms are classified as BIRADS category 3 104.  Prior studies 
evaluating mammograms assigned to the BIRADS 3 category demonstrate variability in 
subsequent follow-up recommendations and clinical management 86, 105. According to the 
BIRADS classification schema, these women are recommended to come back at somewhere 
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between 6-12 months based on recommendation from the radiologist, constituting short 
interval or immediate follow-up 16. We found it important to differentiate between women 
with and without immediate follow-up recommendation so as not to incorrectly penalize 
women who may appear to be having delayed follow-up but are in fact following radiologist 
recommendation. Positive screening mammograms that were categorized as BIRADS 3 
without recommendation for immediate follow-up were excluded from the complete case 
analysis. When plotting the histogram of time to follow-up after a positive screening 
mammogram we could clearly see two populations.  
	
Figure 13. Comparison of Time to Follow-up (Days) between BIRADS 3 with and without 
Recommendation for Immediate Follow-up 
Sensitivity Analysis: Odds of Delay using Multiple Cutpoints of Time 
In the literature, diagnostic delays of 3-6 months after a positive screening 
mammogram result have been associated with larger tumor size and reduced survival. 
Because the literature offers a range of time thought to impact breast cancer survival I will 
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create separate indicator variables to evaluate multiple cut points of time (30, 60, 90, 120, 
150, 180 days) between date of positive screening mammogram and subsequent diagnostic 
follow-up. I will assess each cut point and evaluate associations between insurance status and 
diagnostic delay. I want to see how altering the cut points used to distinguish a delay in 
diagnostic follow-up impacts the association between insurance status and delay. 
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CHAPTER 4. OVERVIEW OF RESULTS 
Study Population 
 Figure 14 presents a flow diagram of the study population and the various CMR data 
sources used to create the study cohort, as well as outlines study exclusions. The data sources 
used to create the study cohort include a questionnaire completed by the woman on the day 
of the examination, a questionnaire completed by the radiologist, and data on cancer 
outcomes from the North Carolina Central Cancer Registry. Figure 15 presents a histogram 
of age for the study population. The mean age is 57 years. In Figure 16 we see a histogram of 
time to initial diagnostic follow-up after a positive screening mammogram. The majority of 
women receive initial diagnostic follow-up within 60 days of their positive screening 
mammogram. 
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Figure 14. Flow Diagram of Study Population Creation and Data Sources 
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Figure 15. Histogram of Age for the Study Population 
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Figure 16. Histogram of Time to Initial Follow-up for the Study Population 
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Table 11. Comparison of those with and without Follow-up 
 No 
Follow-up 
(%) 
(n=4010) 
Follow-up 
(%) 
Chi-square 
statistic 
p 
Race/Ethnicity   8.78 0.0124 
White, Non-Hispanic 81.62 81.06 
Black, Non-Hispanic 13.24 12.08 
Other 2.05 2.26 
Age   6.48 0.0903 
40-49 38.15 32.04 
50-59 28.60 28.54 
60-64 10.37 10.92 
65+ 22.87 28.51 
Education   40.31 <.0001 
< High school graduate 8.35 7.42 
High school graduate 21.60 25.37 
Some college/technical 
school 
18.75 22.82 
College or post college 
graduate 
17.23 23.78 
Patient Location   15.90 <.0001 
Rural 42.56 61.25 
Urban 57.44 38.75 
Ever Mammogram   3.22 0.0728 
No 8.18 10.70 
Yes 91.82 89.23 
Unknown 0 0.07 
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Time since last 
mammogram 
  51.36 <.0001 
No previous mammogram 8.18 10.70 
With 1 year (0-11 months) 9.25 7.31 
1-2 years (12-35 months) 64.71 62.22 
3-4 years (36-59 months) 6.21 6.18 
5 years or more (60+ 
months) 
3.84 4.92 
Breast Density   29.60 <.0001 
Entirely fatty 2.06 2.75 
Scattered fibroglandular 
densities 
47.64 44.03 
Heterogeneously dense 43.83 44.33 
Extremely dense 6.48 8.89 
Race/Ethnicity and Follow-up Time after a Positive Screening Mammogram 
In this study we observed differences in follow-up time by race. Specifically, Native 
Americans experienced a median follow-up of 19 days (IQR=0-210) compared with a 
median of 13 days (IQR=0-182) for White women. Women reporting Hispanic ethnicity 
experienced a median follow-up time of 15 days (IQR=3-117). Table 12 presents the median 
follow-up times and interquartile range (IQR) by race/ethnicity. 
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Table 12. Median Follow-up Times and Interquartile Range (IQR) by Race/Ethnicity 
 Median time 
to follow-up 
(days) 
Interquartile 
Range 
(IQR)a 
Cohort  13 1-181 
Race/Ethnicity   
American Indian 19 0-210 
Asian 13 0-59 
Black 12 0-182 
White 13 0-182 
Other/Multi-
racial 
15 0-176 
Hispanic 15 3-177 
Unknown 13 0-36 	
Figure 17 displays a plot of the Kaplan Meier estimates by insurance status for the 
study cohort. Women reporting no insurance have a longer time to follow-up after a positive 
screening mammogram when compared to women reporting other insurance status.  
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Figure 17. Kaplan Meier Plot of the Estimates for the Survival Function by Insurance Status 
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CHAPTER 5: INSURANCE-BASED DIFFERENCES IN TIME TO DIAGNOSTIC 
FOLLOW-UP AFTER POSITIVE SCREENING MAMMOGRAPHY1 
Introduction 
Screening mammography has been associated with as much as a 20% reduction in 
breast cancer mortality among women ages 40-74 years 4, 7 and mammography remains the 
preferred method for breast cancer screening in the U.S. 7 An estimated 54-60% of breast 
cancers are detected via screening mammography 9, 10, 106 highlighting its importance in 
breast cancer detection. Approximately 10% of screening mammograms require additional 
follow-up imaging and about 2% require a biopsy 15, 107. A dimension of screening that may 
impact breast cancer mortality is the receipt of appropriate and timely follow-up after a 
positive screening mammogram, especially if the follow-up delays necessary treatment. 
Breast cancer screening via mammography is only effective in reducing mortality if followed 
by timely diagnosis and treatment.  
Currently, the only U.S. guideline regarding the length of time in which follow-up 
should occur after a positive screening mammogram comes from the Centers for Disease 
Control and Prevention (CDC). The CDC guidelines recommend women with a positive 
screening mammogram complete diagnostic work-up of a positive screening mammogram 
within 60 days of the initial positive screen 108, 109. Delayed (>60 days, based on the CDC 
guideline, as defined in the literature) follow-up after a positive screening mammogram may 
																																								 																					
1 This chapter was taken from: Durham DD, Robinson WR, Lee SS, Wheeler SB, Reeder-Hayes KE, 
Bowling JM, Olshan AF, and Henderson LM. Insurance-based differences in time to diagnostic 
follow-up after positive screening mammography. Submitted to Cancer, Epidemiology, Biomarkers & 
Prevention in February 2016. 
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contribute to disparities in breast cancer outcomes and subsequently mortality since follow-
up times of 3-6 months have been associated with larger tumor size at diagnosis and reduced 
survival 14, 34, 54, 55, 110.  
Many factors may contribute to prolonged initiation of diagnostic follow-up after a 
positive screening mammogram result 2. Healthcare system factors known to influence 
receipt of appropriate diagnostic follow-up include adequate communication with health care 
professionals, physician referral, and facility type 57, 111. Prior studies have investigated 
patient factors such as race, education, and rural/urban residence that influence diagnostic 
follow-up time 56. However, few studies have examined the influence of insurance on 
diagnostic follow-up time. Insurance status refers to whether someone is uninsured or insured 
and among those with insurance designates the specific insurance provider. 
Although the impact of insurance status as a determinant of breast cancer care (access 
to screening, stage at diagnosis, receipt of treatment) has been well-documented 39, 40, 58, 101, 112, 
113, the effect of insurance status on time to diagnostic follow-up initiation after a positive 
screening mammogram is not well understood. Associations may vary by insurance status and 
prior studies often include members of a single insurance status or combine multiple insurance 
groups. The primary objective of this study is to assess the association between insurance status 
and the time to initiation of diagnostic follow-up after a positive screening mammogram in a 
large, racially diverse population-based breast cancer screening population.   
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Materials and Methods 
Data and Study Population 
We use data from the Carolina Mammography Registry (CMR), a National Institutes 
of Health (NIH) funded, population-based breast imaging registry in North Carolina. CMR is 
an active member of the Breast Cancer Surveillance Consortium (BCSC) 82 and collects data 
from women undergoing breast imaging at community radiology facilities, from radiologists 
performing the imaging examinations, and from pathology data collected by the breast 
imaging facilities. The CMR data include patient demographics, patient risk factors (such as 
breast density and family history of breast cancer), the type of imaging performed, the reason 
for the examination, and the radiologists’ assessment and recommendation for follow-up. 
These data are linked with cancer outcomes from the North Carolina Central Cancer Registry 
(NC-CCR) and abstracted hospital pathology reports as well as with vital status data from the 
State Center for Health Statistics.  
This study includes data collected between 1995-2010 from women ages 40 and older 
undergoing screening mammography with non-missing insurance status and no personal 
history of breast cancer. At the time of the mammogram, the radiologist recorded whether the 
examination was a screening or diagnostic mammogram. A screening mammogram was 
defined using BCSC definitions 10, 12 and includes routine views of the breast among women 
without breast symptoms such as pain or lump. To be considered positive, the screening 
mammogram had to be assigned a Breast Imaging Reporting and Data System (BI-RADS) 
assessment of 0 (needs additional imaging), 4 (suspicious abnormality), 5 (highly suggestive 
of malignancy), or 3 (probably benign finding) coupled with the radiologist’s 
recommendation for immediate follow-up (surgical consult, biopsy, or fine needle aspiration) 
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12, 16. Among women with more than one positive screening mammogram in CMR, one 
positive screening exam was randomly selected. Women 65 years and older reporting no 
insurance were excluded from analyses due to small numbers (n=24, less than 1% of the 65+ 
sample). 
Exposure and Outcome Assessment  
Insurance paying for the exam are self-reported by the woman at the time of the 
screening mammogram and comprises the following categories: no insurance, Medicaid only, 
Medicare only, Medicare & Medicaid (usually referred to as “dual coverage”), Medicare & 
private, and private only. Initial diagnostic follow-up was defined as the first of subsequent 
breast imaging (such as diagnostic mammography, breast ultrasound, MRI) or breast biopsy 
following the positive screening mammogram. For each positive screening mammogram, we 
looked forward one year for subsequent imaging or biopsy and then ascertained the time until 
initial diagnostic follow-up as the number of days from the positive screening mammogram 
until the date of the first follow-up event, censoring at 365 days.  A woman could have a 
follow-up time of zero days if the positive screening mammogram and the first diagnostic 
follow-up event were performed on the same day.  
Covariates 
Covariates of interest included demographic information as reported by the woman at 
the time of the mammogram using a standard patient questionnaire. These variables included: 
age (age at time of positive screening mammogram); race (Black, White, Asian, Hispanic, 
American Indian, Other); and education (less than high school diploma, high school graduate 
or equivalent, some college, college graduate). 
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An indicator of urban/rural patient residence was based on the zip code of the patient-
provided address at the time of the positive screening mammogram. Breast density was 
reported at the time of the positive screening mammogram by the interpreting radiologist 
using BI-RADS breast density classifications of almost entirely fatty, scattered 
fibrograndular densities, heterogeneously dense, and extremely dense 114, 115. At the time of 
the screening mammogram, women self-reported family history of a first-degree relative with 
breast cancer and history of a breast biopsy. The facility at the time of screening 
mammography was categorized as Hospital, Radiology private office, Comprehensive cancer 
center, Hospital outpatient center, or Primary care. Primary care included OB/GYN office, 
mobile screening units, and multispecialty clinics. The following covariates were included in 
both the adjusted time-to-event models and the adjusted logistic regression models for 
comparison with current literature on screening mammography or because they are risk 
factors for breast cancer: age, race (Black non-Hispanic, White non-Hispanic, and Other), 
education, breast density, history of breast biopsy, family history of breast cancer, and 
facility type. 
Statistical Analysis 
We described time to initial diagnostic follow-up for the study population by 
insurance status and age group at the time of the positive screening mammogram. Analyses 
were conducted separately for women younger than 65 years and for women 65 years and 
older at the time of the positive mammographic result because of the age-specific eligibility 
requirements of Medicare.   
We calculated median time until initial diagnostic follow-up with interquartile range 
(IQR) and used the Kaplan-Meier estimator to construct survival curves within strata of 
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insurance 101. We confirmed the proportional hazards assumption by graphing the logs of the 
cumulative hazards. We then used the Cox proportional hazards regression model to estimate 
hazard ratios (HR) and 95% confidence intervals (CI) to evaluate the association between 
insurance status and initial diagnostic follow-up after a positive screening mammogram. 
Women were administratively censored at 365 days after the positive screening mammogram 
if a follow-up event did not occur or at the time that the mammography facility at which they 
received their positive screening mammogram stopped reporting data to the CMR (if 
applicable), whichever came first.  
We also used multivariable logistic regression to estimate odds ratios and 95% 
confidence intervals for time to initial follow-up beyond 60 days based on the CDC 
guidelines. In both sets of models, the referent group for women younger than 65 years was 
Private insurance alone. The referent group in the models for ages 65 and over was Medicare 
& Private; among the older women, it was the most populous category for this age group. 
These models include women who do not receive follow-up within the study window. All p-
values were two-sided and α <0.05 was considered statistically significant. Statistical 
analyses were performed using SAS v9.2 (SAS Institute, Cary NC). This ancillary study of 
CMR data was conducted with approval from the Institutional Review Board at The 
University of North Carolina at Chapel Hill. 
Results 
In the study population, approximately 81% of women included in the study self-
reported their race as non-Hispanic White and 12% reported non-Hispanic Black (Table 13). 
The mean age for the study population was 57 years (SD=12). The majority of women under 
65 years of age reported having private insurance (89%) followed by Medicare plus private 
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(18%). Though Black women under 65 years represented 13% of the age group, they 
accounted for 16% of the uninsured in that age group. The majority (60%) of women 65 
years and older reported Medicare & private insurance followed by Medicare only (22%).  
For the study cohort, the median time until initial diagnostic follow-up after a positive 
screening mammogram was 12 days (IQR 7-22 days). Women under 65 years with no 
insurance experienced a median follow-up of 16 days (IQR 8-37) compared to women with 
private insurance, who had a median of 12 days (IQR 7-21) (Table 14). Among women 65 
years and over, those with Medicare & Medicaid experienced a median follow-up of 14 days 
(IQR 8-29) while women with private insurance experienced a median of 12 days (IQR 7-
21). The Kaplan Meier survivor curves, stratified by insurance status for women under 65 
years of age and those 65 and over, show differences by insurance status in initial follow-up 
time were observed for the 365 day study period (p<.01). (Figure 18).   
In the time-to-event analysis, approximately 10% of women had no follow-up in the 
study period (365 days) after their positive screening mammogram (Table 14). Women who 
did not receive follow-up within the study period were more likely to be non-white, 
uninsured, have less education, and have more dense breasts (data not shown). Among 
women who received no follow-up during the study period, there were slight differences in 
ever receiving follow-up by age group. Women 65 years and over were more likely to 
receive follow-up within the study period of 365 days than women under 65 years (8% 
versus 11% with no follow-up within 365 days, respectively).  
In the adjusted time-to-event model for women under 65 years, when compared to 
women with private insurance, uninsured women experienced a longer time to initial 
diagnostic follow-up with HR=0.47 (95% CI=0.25-0.89) (Table 15). Among women under 
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65 years, we did not observe statistically significant differences between private insurance 
only (the referent group) and the following insurance groups: Medicaid only, Medicare only, 
Medicare & Medicaid, and Medicare & private, although all but Medicare & private had HRs 
less than 1.0. In the adjusted model, among women 65 years and over, when compared to 
those with Medicare plus private insurance, women with private insurance experienced a 
faster time to initiation of follow-up with HR=2.09 (95% CI=1.27-3.44). Among women 65 
years and over we did not observe statistically significant differences between Medicare & 
private insurance (the referent group) and the following insurance groups: Medicare and 
Medicare & Medicaid. 
In the logistic regression analysis, about 12% of all women in the study did not 
receive initial diagnostic follow-up within 60 days of their positive screening mammogram as 
recommended by CDC guidelines. This 12% includes women who received follow-up 
beyond 60 days and those who do not receive follow-up within 365 days (Table 14). Among 
women under 65 years, nearly 18% of women without insurance received initial diagnostic 
follow-up after 60 days compared to 11% of women with private insurance. Women 65 years 
and over were slightly more likely than younger women to have follow-up greater than 60 
days (13%). Among women 65 years and over, women reporting Medicare & Medicaid were 
slightly more likely to receive initial follow-up after 60 days.  
In the adjusted logistic regression model for women under 65 years, when compared 
to women with private insurance, uninsured women had increased odds of delay (OR 1.59, 
95% CI 1.31-1.94) (Table 16). No other insurance groups in this age among women <65 
years indicated significant odds of delay. Among women 65 years and over, we did not 
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observe statistically significant differences between Medicare & private insurance (the 
referent group) and the other insurance groups in adjusted models.  
Discussion 
We examined insurance as a predictor of time to initial diagnostic follow-up in a large 
population-based mammography registry and found that among women less than 65 years of 
age, women without insurance experienced a longer time to initial diagnostic follow-up 
compared to women with private insurance. It is important to note that the difference in days 
to initiation between the insurance groups is small and may not represent a clinically 
significant difference. Among women ages 65 and older, women with private only insurance 
experienced a faster time to initial diagnostic follow-up compared with women with 
Medicare and private insurance. These women may be more economically advantaged with 
increased access to care. In the multivariable logistic regression models, uninsured women 
less than 65 years of age were 1.59 times more likely to experience a delay when compared 
to the privately insured in the same age group. There were no observed statistically 
significant associations between insurance status and delay among women 65 years of age 
and over.  
Few population-based studies have examined the impact of insurance status and time 
until initial diagnostic follow-up after a positive screening mammogram. A study of time 
between initial consult and diagnosis reports hazard ratio estimates of four levels of 
insurance and the uninsured, but includes women with symptoms 116. Other studies focused 
on homogenous populations including, for example, only Medicaid beneficiaries 29, 31, 56. In 
many studies of breast cancer outcomes, Medicaid enrollment is a predictor of poor health 
outcomes. 40, 76, 116, 117 In this study, we did not find that Medicaid insurance was associated 
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with a longer time to initial diagnostic follow-up after a positive screening mammogram, 
regardless of age group.  
Other studies combined insurance groups, specifically Medicare and Medicaid to 
create a public or government category and compared this to all others included in the study 
21, 27, 41, 43, 118. Similarly, other studies grouped Medicaid and those without insurance 119, 
which may mask benefits in time to follow-up experienced by those with Medicaid. This may 
lead to less informative conclusions because eligibility requirements for government-
sponsored insurance programs such as Medicare and Medicaid are largely based on specific 
guidelines for age, income status, and disability status 120, 121. Additionally, the insurance 
categories may represent populations with varying barriers for seeking care such as disability 
or comorbidities. An urban hospital-based study found that women with private insurance 
reached resolution of their positive mammogram faster than those with government 
insurance, a combination of people with Medicare and Medicaid 48. A recent study of women 
enrolled in a patient navigation program assessing the impact of barriers to care after a 
positive screen, one of which was insurance, reported that women with an insurance barrier 
experienced a longer time to diagnostic follow-up after a positive screening mammogram 
(HR=0.85, 95% CI=0.74-0.97) 122. Another study comparing those with no insurance to those 
with only hospitalization insurance found that insurance was not associated with completing 
diagnostic follow-up123. While these studies provided helpful information regarding a broad 
effect of insurance on resolution of a positive mammogram, they do not provide information 
on how resolution of a positive screening mammogram may vary by specific categories of 
insurance.  
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Median follow-up times to initial diagnostic follow-up in the current study were 
similar to prior studies.11, 43, 124 Specifically, a study of women attending an urban academic 
medical center in a federally designated medically underserved area reported a median 
follow-up time (defined as days between the positive mammogram and additional imaging) 
of 14 days 43. However, this study did not investigate differences by insurance status. Other 
studies report median time to complete follow-up between 20 and 50 days 19, 21, 22, 123. 
In the current time-to-event analysis, 10% of women had no initial diagnostic follow-
up within 365 days of their positive screening mammogram. It is challenging to compare our 
results regarding no follow-up with other studies as many studies fail to describe women with 
no follow-up after a positive screening mammogram 22, 125, 126 or exclude these women from 
the analysis 127. It may be the case that women who never receive follow-up are different 
than those who are delayed but do eventually receive follow-up.  
In the current study, nearly 12% of women did not receive initial diagnostic follow-up 
within 60 days after a positive screening mammogram. A study of CDC’s National Breast 
and Cervical Cancer Early Detection screening program found that 20% of women did not 
receive any diagnostic follow-up within 60 days of a positive screening mammogram 29. 
Other studies of complete diagnostic follow-up after a positive screening mammogram report 
similar results: 20-40% of women receive diagnostic follow-up more than 60 days after a 
positive screening mammogram or fail to receive diagnostic follow-up entirely 19, 29-32.  These 
estimates are slightly higher than those reported in our study and may be explained by 
differences in study populations, since these studies were conducted in hospitals or academic 
medical centers and our population represents women screened in community practices. 
Though there are no national or population-based estimates for the proportion of positive 
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screening mammograms that do not receive diagnostic follow-up with which to compare, our 
study falls within the reported range (9-50%) from other studies 5, 32, 128, 129.  
The strengths of our study include the use of prospectively collected data, a diverse 
population, and large sample size. Moreover, the CMR data are longitudinal providing the 
opportunity to follow individual women receiving screening mammograms and subsequent 
breast imaging and biopsy. Prior studies were often limited by small sample sizes or focused 
on one insurance status and did not allow for examination by more insurance categories 
while also including the uninsured. In addition, previous studies frequently relied on 
administrative databases designed for billing purposes rather than research, and thus lack 
crucial information on the mammogram result. Exclusive use of patient questionnaires or 
medical records may lack complete dates of services to ensure sufficient documentation of 
time until diagnostic follow-up. In contrast, the CMR data contain detailed information on 
breast imaging procedures performed including the date of procedure as well as the 
radiologists’ interpretation of the mammogram. 
Our study also has several limitations. Insurance status from the CMR is self-reported 
and may not be completely accurate. We are unable to confirm the payer for each imaging 
and biopsy received during the study period. However, other studies found that self-report of 
insurance payer can be fairly accurate for both mammography 130 and non-mammography 
settings 131, 132 It is also possible that some follow-up visits were not captured in the CMR if a 
woman received her diagnostic follow-up care outside of the CMR catchment area. Finally, 
there may be bias due to unmeasured confounding. Some factors that may influence 
healthcare outcomes are not collected by CMR such as income, co-morbidities, access to 
transportation, social support, etc. It is possible that these factors may impact the patient’s 
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screening behaviors such as the ability to undergo diagnostic procedures or the frequency 
with which they interact with the healthcare system and could explain the differences in 
follow-up observed in this study 133. 
In summary, to maximize the benefits of screening mammography it is important that 
women receive appropriate and timely follow-up after a positive screening mammogram, 
especially if the follow-up delays necessary treatment. Additionally, it is important to 
understand how insurance impacts follow-up after a positive screening mammogram. We 
found differences in time to initial diagnostic follow-up after a positive screening 
mammogram by insurance status as well as by age group. It remains to be seen if the 
differences in initial follow-up after a positive screening mammogram by insurance status 
represent variation of clinical significance, however, our findings that 8-14% of women with 
a positive screening mammogram do not receive follow-up within 365 days is concerning 
since this may have a significant clinical impact on time to diagnosis and receipt of 
treatment. Future research on the variation in the proportion of women with no follow-up at 
365 days by insurance status should be undertaken to further understand how to target groups 
experiencing longer time to follow-up.  
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Table 13. Demographic Distribution of Women Ages 40 Years and Older Receiving a Positive Screening Mammogram between 
1995-2010 by Insurance Status Stratifying by Women Younger than 65 Years and Women 65 Years and Older 
 
 
 
All 
Insurance  
No 
Insurance 
Medicaid 
Only 
Medicare 
Only 
Medicare 
& 
Medicaid 
Medicare 
& Private 
Private 
Only  
N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
Age <65 Years        
Total 31,194 916 (3) 934 (3) 634 (2) 475 (1) 592 (2) 27,643 (89) 
Race/Ethnicity        
Black, Non-
Hispanic 3,916 (13) 144 (16) 
374 (40) 
165 (26) 
178 (37) 
108 (18) 
2,947 (11) 
White, Non-
Hispanic 
24,969 
(80) 665 (73) 
458 (49) 
423 (67) 
269 (57) 
444 (75) 
22,710 (82) 
Other 859 (3) 82 (9) 40 (4) * * 15 (3) 703 (3) 
Unknown 1,450 (5) 25 (3) 62 (7) * * 25 (4) 1,283 (5) 
Age (years)        
40-44 7,307 (23) 212 (23) 276 (30) 64 (10) 62 (13) 35 (6) 6,658 (24) 
45-49 7,040 (22) 220 (24) 204  (22) 98 (15) 97 (20) 72 (12) 6,349 (23) 
50-54 6,648 (21) 184 (20) 184 (20) 121 (19) 105 (22) 109 (18) 5,945 (22) 
55-59 5,590 (18) 144 (16) 159 (17) 165 (26)     109 (23) 162 (27) 4,851 (18) 
60-64 4,609 (15) 156 (17) 111 (12) 186 (29) 102 (21) 214 (36) 3,840 (14) 
Education        
<High School 1,580 (5) 140 (15) 227 (24) 107 (17) 141 (30) 59 (10) 906 (3) 
High school/GED 6,692 (21) 295 (32) 273 (29) 204 (32) 142 (30) 183 (31) 5,595 (20) 
Some college 7,286 (23) 206 (22) 167 (18) 130 (21) 64 (13) 140 (24) 6,579 (24) 
College graduate 8,372 (27) 103 (11) 59 (6) 48 (8) 25 (5) 103 (17) 8,034 (29) 
Unknown 7,264 (23) 172 (19) 208 (22) 145 (23) 103 (22) 107 (18) 6,529 (24) 
Age 65+ Years        
Total 11,832 . 192 (2) 2,617 (22)      753 (6) 7,087 (60) 1,183 (10) 
Race/Ethnicity        
Black, Non-
Hispanic 1,226 (10) . 
46 (24) 
363 (14) 
285 (38) 
422 (6) 
110 (9) 
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All 
Insurance  
No 
Insurance 
Medicaid 
Only 
Medicare 
Only 
Medicare 
& 
Medicaid 
Medicare 
& Private 
Private 
Only  
N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
White, Non-
Hispanic 9,883 (83) . 
132 (69) 
2,115 (81) 
408 (54) 
6,245 (88) 
983 (83) 
Other 134 (1) . * 27 (1) * 71 (1) 19 (2) 
Unknown 589 (5) . * 112 (4) * 349 (5) 71 (6) 
Age (years)        
65-69 4,342 (37) . 80 (42) 920 (35) 222 (29) 2,354 (33) 766 (65) 
70-74 3,320 (28) . 49 (26) 753 (29) 204 (27) 2,086 (29) 228 (19) 
75+ 4,170 (35) . 63 (33) 944 (36) 327 (43) 2,647 (37) 189 (16) 
Education        
<High School 1,632 . 62 (32) 457 (17) 297 (39) 705 (10) 111 (9) 
High school/GED 3,767 . 58 (30) 892 (34) 195 (26) 2,277 (32) 345 (29) 
Some college 2,291 . 20 (10) 403 (15) 65 (9) 1,564 (22) 239 (20) 
College graduate 1,579 . 17 (9) 267 (10) 25 (3) 1,106 (16) 164 (14) 
Unknown 2,563 . 35 (18) 598 (23) 171 (23) 1,435 (20) 324 (27) 
*Cell counts <11 have been suppressed 
Women reporting no insurance 65 years and older were removed from the models due to small sample size (n=24) 
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Table 14. Median and Mean Time to Initial Diagnostic Follow-up in Days, Proportion with 
Follow-up Greater than 60 Days, and Proportion with No Follow-up for Women Ages 40 
Years and Older Receiving a Positive Screening Mammogram between 1995-2010 by 
Insurance Status, Stratified at 65 Years of Age 
 
Insurance 
Median 
(IQR) a 
Mean 
(SD) 
% with follow-
up > 60 days 
% with no 
follow-up 
within 365 days 
All 12 (7-22) 43 (116) 11.9 10.1 
Age <65 years     
No Insurance 16 (8-37) 62 (166) 17.5 13.8 
Medicaid Only 14 (7-27) 47 (121) 12.9 8.5 
Medicare Only 15 (8-28) 53 (159) 15.5 9.6 
Medicare & Medicaid 14 (8-29) 60 (220) 14.0 9.5 
Medicare & Private 13 (7-24) 42 (80) 13.0 8.2 
Private Only 12 (7-21) 40 (108) 11.0 10.9 
All, <65 12 (7-22) 41 (114) 11.4 10.8 
Age 65+ years     
Medicare Only 13 (7-26) 54 (135) 14.5 8.8 
Medicare & Medicaid 14 (8-29) 55 (142) 15.9 8.8 
Medicare & Private 12 (7-21) 44 (118) 12.5 7.7 
Private Only 12 (7-21) 40 (87) 11.5 10.6 
All, 65+ 13 (7-22) 46 (121) 13.2 8.3 
a Interquartile range (IQR) reported as a range; from the 25th percentile to the 75th percentile 
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Note: The tick marks in the figure represent observations as each woman experiences a follow-up 
event (additional mammography, breast ultrasound, MRI, or biopsy). 
Figure 18. Comparison of the Kaplan-Meier Estimates of the Survivor Curve Stratified by 
Insurance Status for Women <65 Years and Women 65 and Older Receiving a Positive 
Screening Mammogram between 1995-2010 
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Table 15. Unadjusted and Adjusted Hazard Ratio (HR) Estimates and 95% Confidence 
Intervals (CI) of the Association between Insurance Status and Time to Initial Diagnostic 
Follow-up after a Positive Screening Mammogram for Women Younger than 65 Years and 
Women 65 Years and Older between 1995-2010 
 Unadjusted Adjustedb 
Insurance  
Hazard 
Ratio 95% CI p-valuea 
 
Hazard 
Ratio 
 
 
95% CI 
 
 
p-valuea 
Age <65 Years       
No Insurance 0.59 0.33-1.06 0.08 
 
0.47 
 
0.25-0.89 
 
0.02 
Medicaid Only 0.75 0.44-1.28 0.28 
 
0.81 
 
0.46-1.42 
 
0.46 
Medicare Only 0.86 0.44-1.67 0.65 
 
0.95 
 
0.47-1.91 
 
0.88 
Medicare & 
Medicaid 0.63 0.32-1.24 0.18 
 
0.50 
 
0.24-1.02 
 
0.06 
Medicare & private 2.16 1.07-4.38 0.03 
 
1.81 
 
0.86-3.83 
 
0.12 
Private Only 
(Referent) 1.00 . . 
 
1.00 
 
. 
 
. 
Age 65+ Years       
Medicare Only 0.89 0.66-1.20 0.44 0.97 0.70-1.34 0.83 
Medicare & 
Medicaid 0.79 0.49-1.27 0.33 
0.99 0.57-1.74 0.99 
Medicare & private 
(Referent) 1.00 . . 
 
1.00 
 
. 
 
. 
Private Only 1.92 1.22-3.03 <.01 2.09 1.27-3.44 <.01 
a All p-values are two-sided and α<0.05 was considered statistically significant 
b The adjusted model includes race, education, breast density, categorical age, history of breast 
biopsy, family history of breast cancer, and facility type 
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Table 16. Unadjusted and Adjusted Odds Ratio (OR) Estimates and 95% Confidence 
Intervals (CI) of the Association between Insurance Status and Time to Initial Diagnostic 
Follow-up of More than 60 Days After a Positive Screening Mammogram for Women 
Younger than 65 Years and Women 65 Years and Older Between 1995-2010 
 Unadjusted Adjustedb 
Insurance  
Odds 
Ratio 95% CI p-valuea 
 
Hazard 
Ratio 
 
 
95% CI 
 
 
p-valuea 
Age <65 Years       
No Insurance 1.61 1.38-1.89 <.01 
 
1.59 
 
1.31-1.94 
 
<.01 
Medicaid Only 0.97 0.82-1.14 0.70 
 
1.00 
 
0.82-1.21 
 
0.96 
Medicare Only 1.19 0.98-1.43 0.08 
 
1.21 
 
0.97-1.52 
 
0.09 
Medicare & Medicaid 1.09 0.88-1.36 0.43 
 
1.09 
 
0.85-1.42 
 
0.49 
Medicare & private 0.95 0.77-1.17 0.62 
 
1.10 
 
0.87-1.40 
 
0.43 
Private Only 
(Referent) 1.00 . . 
 
1.00 
 
. 
 
. 
Age 65+ Years       
Medicare Only 1.21 1.08-1.35 <.01 1.14 0.99-1.30 0.06 
Medicare & Medicaid 1.29 1.08-1.56 <.01 0.96 0.76-1.20 0.73 
Medicare & private 
(Referent) 1.00 . . 
 
1.00 
 
. 
 
. 
Private Only 1.12 0.96-1.31 0.16 1.14 0.95-1.36 0.16 
a All p-values are two-sided and α<0.05 was considered statistically significant 
b The adjusted model includes race, education, breast density, categorical age, history of breast 
biopsy, family history of breast cancer, and facility type 
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CHAPTER 6: CLINICAL PATHWAYS OF DIAGNOSTIC FOLLOW-UP AFTER A 
POSITIVE SCREENING MAMMOGRAM1 
Introduction 
Though most women undergoing routine screening mammography will receive a 
normal mammogram, for any one screening examination, about 10% of women will have a 
positive screening mammography result 15. Positive screening mammograms require 
diagnostic follow-up and may include multiple imaging exams with or without biopsy 
(referred to as the diagnostic follow-up pathway). Subsequent imaging and biopsy vary 
depending upon the result of the index positive screening mammogram or other factors such 
as a previous positive screening mammogram and the assessment result of the exam 6, 16. The 
current literature on the enumeration of the series of subsequent clinical imaging and biopsy 
following a positive screening mammogram is largely conceptual but explicitly calls for 
“definitions of the steps and interfaces” as priorities for appropriate intervention and study 
design 46, 128, 134.  Failure to complete follow-up after a positive screening mammogram may 
reduce the benefit of early detection and greatly undermines the effectiveness of the screen 
and may contribute to disparities in cancer outcomes. As outlined in the National 
Comprehensive Cancer Network (NCCN) breast cancer clinical practice guideline, diagnostic 
follow-up pathways may include a single diagnostic mammogram or may be much more 
complicated and include multiple diagnostic imaging exams and biopsy, which usually 
																																								 																					
1	This chapter was taken from: Durham DD, Robinson WR, Lee SS, Wheeler SB, Reeder-Hayes KE, 
Bowling JM, Olshan AF, and Henderson LM. Clinical pathways of diagnostic follow-up after a 
positive screening mammogram. To be submitted to a peer-reviewed journal in Spring 2016. 	
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signals the end of the diagnostic process17. While the recommended pathways are presented 
by assessment category, these recommendations make no mention of the quality of one 
pathway compared to another pathway. These pathways may also involve a transition 
between type of provider. The Institute of Medicine (IOM) identifies transitions in care as a 
challenge for quality improvement.  
Research conducted by Hubbard and colleagues demonstrates that clinical factors 
such as imaging modality is associated with diagnostic follow-up pathways, however, non-
clinical factors may also play a role. Insurance status has been shown to be associated with 
access to screening mammography and delays in follow-up after a positive screening 
mammogram48, 58, 112. An increase in the use of biopsy after a positive screening 
mammogram 135 and after a diagnostic mammogram, specifically for women over 50 years of 
age, 136 has been reported. It is possible that insurance providers may differ in the subsequent 
imaging examinations covered, out-of-pocket expenses for these exams, or may require 
approvals in advance of the exam 137.  However, it is not known the extent to which 
insurance status is associated with the imaging and biopsy subsequent to a positive screening 
mammogram.  
Public health professionals acknowledge the need for interventions to aid patients 
with receipt of follow-up care after a positive cancer screening result. There has also been a 
call for personalized breast cancer screening and subsequent monitoring138. For these 
interventions to be successful, public health professionals must know what follow up care is 
necessary to resolve the positive screening exam. Knowledge of subsequent imaging and 
biopsy may also be useful for health services researchers interested in model inputs for 
cancer care outcomes research. In order for patient level interventions and patient level care 
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to be successful we must be able to enumerate the diagnostic pathways a woman may 
experience after a positive screening mammogram and understand the impacts of insurance 
status.   
To our knowledge, one study has described the series of imaging and biopsy 
procedures for diagnostic follow-up pathways after positive screening mammography33. This 
study did not assess the impacts of insurance on the diagnostic follow-up pathways. Given 
the importance of insurance status for other breast cancer outcomes, the primary objectives of 
this study were to describe the series of diagnostic follow-up women experience after a 
positive screening mammogram by insurance status and assess the association between 
insurance status and receipt of biopsy after a positive screening mammogram. 
Methods 
Data and Study Population 
We use data from the Carolina Mammography Registry (CMR), a National Institutes 
of Health (NIH) funded, population-based breast imaging registry in North Carolina. CMR is 
an active member of the Breast Cancer Surveillance Consortium (BCSC) 82 and prospectively 
collects data from women undergoing breast imaging at community radiology facilities and 
radiologists performing the imaging examinations. The CMR data are compiled using 
multiple data sources. The patient file includes information taken from the questionnaire that 
is completed by the woman at the time of the imaging examination. This file provides 
information on demographics, family history of breast cancer, medical history related to 
breast health, and insurance status. Insurance status is self-reported by the woman at the time 
of the examination and includes the following categories: private, Medicare and private, 
Medicare, Medicare and Medicaid, Medicaid, and no insurance. The radiologists’ provide 
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information about the imaging examination performed, breast density, the reason for the 
visit, mammographic findings, and the radiologists’ assessment and recommendation for 
follow-up (radiology file). The patient and radiology data are linked with cancer outcomes 
from the North Carolina Central Cancer Registry (NC-CCR), pathology data from the breast 
imaging facilities, and abstracted hospital pathology reports. The pathology file from these 
sources includes biopsy and surgery follow-up information. These data are also linked with 
vital status data from the State Center for Health Statistics. The patient, radiology, pathology 
and vital status files make up the CMR data. 
The current study includes data collected between 1995-2010 from women ages 40 
and older undergoing screening mammography with non-missing self-reported insurance 
status at the time of the screening mammogram. At the time of the mammogram the 
radiologist recorded whether the examination was a screening or diagnostic mammogram. A 
screening mammogram was defined using BCSC definitions and includes routine views of 
the breast among women without breast symptoms such as pain or lump10. To be classified as 
a positive exam, the screening mammogram had to be assigned a Breast Imaging Reporting 
and Data System (BI-RADS) assessment of 0 (needs additional imaging), 4 (suspicious 
abnormality), 5 (highly suggestive of malignancy), or 3 (probably benign finding) coupled 
with the radiologist’s recommendation for immediate follow-up (surgical consult, biopsy, or 
fine needle aspiration within 6 months or less) 16. For each positive screening mammogram, 
we looked forward one year for subsequent imaging or biopsy and created diagnostic follow-
up pathways based on the order of occurrence of these events. The end of the diagnostic 
follow-up pathway occurred: 1) at the last observed event within 365 days of the index 
screening mammogram, 2) if there was a visit which indicated a return to screening 
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mammography, or 3) if there was a breast cancer diagnosis within 365 days of the index 
positive screening mammogram. In most cases these markers of the end of the diagnostic 
follow-up pathway would indicate the index positive screening mammogram had been 
resolved. Resolved indicates either a return to screening or moving beyond detection into the 
diagnostic phase of cancer care138.  
Covariates 
Covariates of interest included: Age (age at time of positive screening mammogram); 
Race (Black, White, Asian, Hispanic, American Indian, Other); and Education (Less than 
High School Diploma, High School Graduate or Equivalent, Some College, College 
Graduate). Breast density was reported at the time of the positive screening mammogram by 
the interpreting radiologist using BI-RADS breast density classification. The categories for 
breast density were: almost entirely fatty, scattered fibrograndular densities, heterogeneously 
dense, and extremely dense 114. Women self-reported history of breast biopsy, number of 
years since their last screening mammogram, and family history of a first-degree relative 
with breast cancer at the time of the screening mammogram. An indicator of urban/rural 
patient residence was based on the zip code of the patient-provided address at the time of the 
positive screening mammogram. The facility at the time of screening mammography was 
categorized as Hospital, Radiology private office, Comprehensive cancer center, Hospital 
outpatient center, and, Primary care. Primary care included OB/GYN office, mobile 
screening units, and multispecialty clinics. The following covariates were included in the 
multivariable logistic regression models: age, race (Black non-Hispanic, White non-Hispanic, 
and Other), education, urban/rural residency, breast density, history of breast biopsy, family 
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history of breast cancer, BIRADS assessment, years since last mammogram, and facility 
type. 
Exclusions 
Among women with more than one positive screening mammogram observed during 
the 10 years of study observation (n=11,174), one positive screening exam was randomly 
selected. Women with a personal history of breast cancer based on self-report or 
identification in the cancer registry were excluded from analyses. Women 65 years and older 
reporting no insurance were excluded from analyses due to small numbers (n=24, <1% of the 
65 years and over sample). During the study period some facilities ended their participation 
in CMR possibly contributing to an interruption in the observable pathway. Women who had 
a facility end participation in CMR within 365 days of their index positive screening 
mammogram were considered to have had their diagnostic follow-up pathway interrupted 
and were removed from the analysis to ascertain complete diagnostic follow-up pathways 
(n=2,911 or 6% of sample). Similarly, women who had a date of death in the vital status file 
within 365 days of their index positive screening mammogram were removed from the 
analysis (n=289). 
Statistical Analysis 
We summarized the series of diagnostic follow-up pathways a woman may undergo 
in follow-up to her positive screening mammogram. Analyses were conducted separately for 
women younger than 65 years and for women 65 years and older to correspond to the age 
eligibility requirements of Medicare. We categorized the series of examinations for each 
woman by insurance status and presented the most common diagnostic follow-up pathways 
after the index positive screening mammogram. For common diagnostic pathways among 
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women under 65 years of age, we compared the distribution for each category of insurance 
status: private only, Medicare & private, Medicare only, Medicare & Medicaid (dually 
eligible), Medicaid only, and no insurance. For common diagnostic pathways among women 
over 65 years of age, we compared the distribution for each category of insurance status: 
private only, Medicare & private, Medicare only, Medicare & Medicaid (dually eligible), and 
Medicaid only. For each age group we tested for differences by insurance status using the 
Chi-square statistic (χ2). We used multivariable logistic regression to estimate odds ratios 
(OR) and 95% confidence intervals (CI) for the association between insurance and a pathway 
including biopsy for two age groups of women: under 65 years of age and 65 years and over. 
The referent group for women younger than 65 years of age was Private insurance. The 
referent group for ages 65 years and over was Medicare & Private; it was the most populous 
category for this age group.  All p values are two-sided. Tests were considered statistically 
significant at p <0.05. Statistical analyses were performed using SAS Software v. 9.2 (Cary, 
NC). This secondary data analysis was conducted with approval from the Institutional 
Review Board at The University of North Carolina at Chapel Hill.  
Results 
The demographic distribution of the study population is presented in Table 17. 
Among 39,829 positive screening mammograms, approximately 81% of women included in 
the study self-reported their race as non-Hispanic White and 12% reported non-Hispanic 
Black. The mean age for the study population was 57 years (SD=12). Among the study 
population, the majority of women had private insurance (67%) followed by Medicare plus 
private (18%). Only 2% of the study population reported having no insurance at the time of 
their positive screening mammogram. Among women under 65 years of age with private 
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insurance (89%), the majority were white (82%), and had at least a high school education 
(97%). A total of 3% reported having no insurance. The majority (60%) of women 65 years 
and over reported Medicare & private insurance followed by Medicare only (22%) and 
private insurance (10%). Figure 19 displays the observed diagnostic follow-up pathways after 
a positive screening mammogram. Among the study cohort, the most common diagnostic 
resolution pathways following a positive screening mammogram were: 1) diagnostic 
mammography only (72%); 2) diagnostic mammography, ultrasound (11%); and 3) 
diagnostic mammography, biopsy (7%) (Table 18). A total of 6% of the study population 
received no observable follow-up during the study period.   
Ages less than 65 years  
 The most common diagnostic resolution pathways following a positive screening 
mammogram among women under age 65 years were: 1) diagnostic mammography only 
(75%); 2) diagnostic mammography, ultrasound (11%); and 3) diagnostic mammography, 
biopsy (8%) (Table 18). Similar to the overall population, 7% of women under age 65 years 
received no observable follow-up during the study period. Among women under 65 years, 
there were differences in pathway by insurance status (p<0.01). Women reporting no 
insurance were more likely to be included in the no follow-up group (15%). 
Ages 65 years and over 
The most common diagnostic resolution pathways following a positive screening 
mammogram among women age 65 years and over were: 1) diagnostic mammography only 
(73%); 2) diagnostic mammography, ultrasound (10%); and 3) diagnostic mammography, 
biopsy (11%). Women over 65 years of aged were slightly less likely to receive no 
observable follow-up during the study period (6%). In this age group, there were differences 
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in pathway by insurance status (p<0.01). Among women over 65 years of age, women 
reporting Medicaid only, or Medicare and Medicaid were less likely to have experienced the 
diagnostic mammography only pathway.  
Predictors of a pathway including biopsy 
 We observed differences in biopsy use by insurance. Among women under 65 years 
approximately 8% had a pathway that included biopsy whereas in women over 65 years, 11% 
had a pathway with biopsy. In the adjusted logistic regression model, among women under 
65 years of age, women reporting Medicare & Medicaid were more likely to experience a 
pathway including biopsy when compared to women reporting Private insurance (OR=1.68, 
95% CI: 1.05-2.68). Although not statistically significant, all other odds ratio estimates in 
this age category indicated a greater risk of biopsy with the exception of women without 
insurance. Among women under 65 years, those with a college education were less likely to 
receive biopsy (OR=0.72 95% CI: 0.58-0.88). Women in this age category who were 50 
years and older were also more likely to receive biopsy (Table 19). Women reporting no 
insurance were slightly less likely to experience a pathway including biopsy; however, this 
estimate was not statistically significant. Among women 65 years and over, women reporting 
Private insurance were less likely to experience a pathway including biopsy when compared 
to women reporting Medicare & Private insurance (OR=0.53, 95% CI: 0.35-0.79). All other 
odds ratio estimates indicated a biopsy was likely, with the exception of women reporting 
Medicaid, though none of these estimates were statistically significant. Regardless of age, 
women who did not receive follow-up within the study period were more likely to be non-
white, uninsured, and have less education. Women 65 years and over were slightly more 
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likely to receive follow-up within the study period when compared to women under 65 years 
(6% versus 7% with no follow-up within 365 days, respectively). 
Discussion 
In comparing the diagnostic follow-up pathways following routine positive screening 
mammogram by insurance status, we found that among both age groups (<65 years vs. 65+), 
the most common diagnostic resolution pathways following a positive screening 
mammogram were: 1) diagnostic mammography only; 2) diagnostic mammography, 
ultrasound; and 3) diagnostic mammography, biopsy. We also observed differences in the 
diagnostic follow-up pathway by insurance status in both age groups.  Women 65 years of 
age and under were less likely to experience a biopsy. 
The most commonly utilized pathways in our study are similar to those previously 
reported33.  Using data from five mammography registries in the Breast Cancer Surveillance 
Consortium (BCSC), the authors assessed for variations in diagnostic pathways by imaging 
modality (digital or film screening mammography). Hubbard and colleagues presented the 
most common pathways ending in biopsy and those that did not end in biopsy. The three 
most common diagnostic follow-up pathways ending in biopsy were: 1) mammography, 
biopsy; 2) mammography, ultrasound, biopsy; and 3) mammography, ultrasound, biopsy, 
additional biopsy. The three most common diagnostic follow-up pathways not ending in 
biopsy were: 1) mammography; 2) mammography, ultrasound; and 2) ultrasound. The 
authors reported minimal differences in diagnostic follow-up pathways after positive 
screening mammogram between the imaging modalities. In the Hubbard study, 95% of 
positive screening mammograms were followed by diagnostic evaluation, which is slightly 
lower than what we report (6% no follow-up/unobserved).  
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The original hypothesis for the present study was that women reporting private 
insurance would be more likely to experience a biopsy as private insurance is generally 
associated with increased access to care and improved health care outcomes when compared 
to other insurance groups. Since we did not observe this result, it remains to be seen the 
underlying mechanisms that may be influencing the use of biopsy after a positive screening 
mammogram. One possible explanation is that women with private insurance may forego 
biopsy for less invasive methods, particularly advanced imaging such as image-guided 
biopsy or breast MRI.  Patient access to and availability of advanced imaging has been 
shown to be influenced by facility characteristics 139. In a sensitivity analysis we found 
differences in receipt of biopsy by facility type, specifically women receiving follow-up 
imaging at a radiology facility were less likely to receive a biopsy.  The implication for 
women of varying insurance status also remains to be seen. Alternative hypotheses must be 
considered such as radiologist’s preferences and decision-making as influenced by cost. The 
cost of follow-up imaging or biopsy for the patient may vary based on procedure type, 
facility, and negotiated reimbursement rates130 may also influence the decisions of the 
patients as well as the radiologist. It is possible the patients may forgo more expensive 
procedures such as advanced imaging to reduce cost. 
This study adds to the current literature by providing information on the types of 
follow-up care women may receive after a positive screening mammogram by insurance 
status. This information may inform future public health intervention, particularly patient 
navigation programs, by providing specific information regarding imaging and procedures 
used to follow-up positive screening mammography so that interventionists know what types 
of events to expect as they follow women through the course and through any transitions in 
 110 
care if they are needed. Additionally, future research may benefit from these results through 
interventions not only at the individual level (patient navigation) but as interventions at the 
health system level. Understanding the diagnostic pathways a woman experiences may 
inform the ability of organizations to tailor electronic medical records for multiple images of 
different types or staff reminders for referrals.  
The strengths of the study are the use of prospectively collected data, a diverse 
population, and a large sample size. Additionally, we were able to control for known breast 
cancer risk factors such as family history of breast cancer, history of biopsy, and screening 
mammogram assessment. The information gained from this study begins to answer questions 
presented in the conceptual literature such as identifying the specific diagnostic pathways 
experienced. This work has not been presented by insurance status. The information provided 
by this study may also serve to generate hypotheses illuminating the need for future research 
with different populations of women utilizing screening mammography. 
This study has several limitations. First, women were included in the study if they had 
complete insurance information. Insurance status was self-reported and we were unable to 
confirm the payer. Self-reported insurance status has been reported to be less reliable in 
certain datasets132, 140, 141 however, other studies found that self-report of insurance payer can 
be fairly accurate for both mammography 130 and non-mammography settings 131, 132. Women 
receiving routine mammograms may be more aware of their insurance if they have to present 
the information at planned yearly screenings as compared to people seeking care under other 
circumstances. In a sensitivity analysis we collapsed women reporting private insurance only 
with women reporting private and Medicare to assess the potential for difference in estimate 
based on misclassification of the exposure. The estimates changed only slightly and the 
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original inferences remained the same. The no insurance group in this study may be different 
from the no insurance groups in other studies of cancer care because this group is a group 
who has sought care, if only for the initial screening mammogram. Second, the data do not 
include follow-up visits that occurred in another state or at non CMR participating facilities. 
Hence, it is possible that some women may be categorized on a specific pathway in this 
study, for example the diagnostic mammogram only pathway, but may have received 
additional imaging outside of the CMR capture area. Third, some aspects of healthcare 
outcomes are not collected by CMR such as income, co-morbidities, physical and mental 
disability, access to transportation, social support, etc. It is possible that these factors may 
reduce a woman’s screening behaviors such as the ability to receive diagnostic procedures 
after a positive screening mammogram133, 142. These have all been cited as barriers to 
screening access. Without information on covariates such as these, we are unable to estimate 
the impact on receipt of follow-up care. Because of small sample sizes, we were unable to 
make inferences about statistical interaction between insurance status and race. Our results 
should also be interpreted understanding that the findings may not be generalizable to 
national populations. It is possible that we may have misclassified pathway use. In a 
sensitivity analysis, we used combinations of the radiologists’ recommendation for following 
up procedure and timing for next follow-up, cancer diagnosis within 365 days, death within 
365 days, and a return visit for screening as a way to classify diagnostic resolution or the end 
of the diagnostic pathway. Using these variables we were unable to classify about 30% of the 
population as resolved or not resolved. Finally, we were not able to differentiate between 
types of biopsy (core needle biopsy, fine needle biopsy, and surgical biopsy). Use of more 
invasive surgical biopsy has decreased between 1997-2011 143 in favor of minimally invasive 
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and cheaper techniques like core needle biopsy 144 and may have implications for access to 
biopsy by insurance status. 
In summary, the most commonly observed diagnostic resolution pathways following 
a positive screening mammogram were: diagnostic mammography only; diagnostic 
mammography, ultrasound; and diagnostic mammography, biopsy. We observed differences 
in biopsy use by insurance status with women under 65 years who report Medicare & 
Medicaid less likely to experience a pathway that included biopsy and among women 65 
years and older women reporting private insurance less likely to experience a pathway that 
included biopsy. Our study adds to the current literature by providing information on the 
types of follow-up care women may receive after a positive screening mammogram. The 
current study also addresses differences in diagnostic follow-up pathway by insurance status. 
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Figure 19. Observed Diagnostic Follow-up Pathways after a Positive Screening Mammogram of Women ages 40 Years and Older 
Receiving a Positive Screening Mammogram Between 1995-2010 in North Carolina* 
*The most common pathways were included in the analysis. These pathways were: 1) diagnostic mammography only 2) diagnostic mammography, ultrasound; 
and 3) diagnostic mammography, biopsy. 	
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 Table 17. Demographic Distribution of Women Ages 40 Years and Older Receiving a Positive Screening Mammogram between 
1995-2010 by Insurance Status Stratifying by Women Younger than 65 Years and Women 65 Years and Older in North Carolina 
 
 
 
Total 
Insurance 
Private 
Only 
Medicare & 
Private Medicare Only 
Medicare & 
Medicaid 
Medicaid 
Only 
No 
Insurance† 
N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
All Ages 39,829 (100) 26,677 (67) 7,115 (18) 3,013 (8) 1,132 (3) 1,033 (3) 859 (2) 
Age <65 Years        
<65 Total 28,912 (100) 25,608 (89) 545 (2) 596 (2) 443 (2) 861 (3) 859 (3) 
Race/Ethnicity        
Black, Non-Hispanic 3,678 (13) 2,765 (75) 99 (3) 155 (4) 170 (5) 349 (9) 140 (4) 
White, Non-Hispanic 23,196 (80) 21,100 (91) 409 (2) 401 (2) 247 (1) 419 (2) 620 (3) 
Other 783 (3) 639 (82) 15 (2) * * 36 (5) 75 (10) 
Unknown 1,255 (4) 1,104 (88) 22 (2) * * 57 (5) 24 (2) 
Age (years)        
40-44 6,788 (23) 6,179 (91) 35 (<1) 63 (<1) 60 (<1) 248 (4) 203 (3) 
45-49 6,529 (23) 5,887 (90) 64 (<1) 94 (1) 90 (1) 186 (3) 208 (3) 
50-54 6,159 (21) 5,506 (89) 99 (2) 112 (2) 96 (2) 174 (3) 172 (3) 
55-59 5,164 (18) 4,482 (87) 152 (3) 151 (3) 99 (2) 149 (3) 131 (3) 
60-64 4,272 (15) 3,554 (83) 195 (5) 176 (4) 98 (2) 104 (2) 145 (3) 
Education        
<High School 1,482 (5) 849 (57) 56 (4) 99 (7) 132 (9) 215 (15) 131 (9) 
High school/GED 6,248 (22) 5,226 (84) 170 (3) 192 (3) 135 (2) 245 (4) 280 (4) 
Some college 6,735 (23) 6,089 (90) 127 (2) 125 (2) 58 (<1) 147 (2) 189 (3) 
College graduate 7,653 (26) 7,346 (96) 91 (1) 45 (<1) 20 (<1) 54 (<1) 97 (1) 
Unknown 6,794 (23) 6,098 (90) 101 (1) 135 (2) 98 (1) 200 (3) 162 (2) 
Family History Breast 
Cancer  
 
  
  
 
No 23,724 (82) 20,982 (88) 456 (2) 487 (2) 392 (2) 745 (3) 662 (3) 
Yes 2,331 (8) 2,047 (88) 54 (2) 58 (2) 36 (2) 68 (3) 68 (3) 
Unknown 2,857 (10) 2,579 (90) 35 (1) 51 (2) 15 (<1) 48 (2) 129 (5) 
BIRADS Assessment        
0Additional imaging 20,862 (72) 18,608 (89) 388 (2) 418 (2) 311 (1) 622 (3) 515 (2) 
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Total 
Insurance 
Private 
Only 
Medicare & 
Private Medicare Only 
Medicare & 
Medicaid 
Medicaid 
Only 
No 
Insurance† 
N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
3Probably benign 6,107 (21) 5,393 (88) 111 (2) 107 (2) 72 (1) 152 (2) 272 (4) 
4Suspicious  1,734 (6) 1,442 (83) * * * 75 (4) 58 (3) 
5Suggestive of 
malignancy 209 (<1) 
 
165 (79) * * 
 
* 
 
12 (6) 14 (7) 
Age 65+ Years        
65+ Total 10,917 (100) 1,069 (10) 6,570 (60) 2,417 (22) 689 (6) 172 (2) . 
Race/Ethnicity        
Black, Non-Hispanic 1,153 (11) 101 (9) 402 (35) 337 (29) 269 (23) 44 (4) . 
White, Non-Hispanic 9,115 (83) 889 (10) 5,791 (64) 1,952 (21) 367 (4) 116 (1) . 
Other 125 (1) 18 (14) 64 (51) 27 (22) 13 (10) * . 
Unknown 524 (5) 61 (12) 313 (60) 101 (19) 40 (8) * . 
Age (years)        
65-69 4,044 (37) 695 (17) 2,212 (55) 861 (21) 206 (5) 70 (2) . 
70-74 3,083 (28) 204 (7) 1,948 (63) 698 (23) 188 (6) 45 (1) . 
75+ 3,790 (35) 170 (4)  2,410 (64) 858 (23) 295 (8) 57 (2) . 
Education        
<High School 1,509 (14) 101 (7) 663 (44) 414 (27) 273 (18) 58 (4) . 
High school/GED 3,480 (32) 309 (9) 2,097 (60) 839 (24) 180 (5) 55 (2) . 
Some college 2,106 (19) 221 (10) 1,435 (68) 372 (18) 61 (3) 17 (<1) . 
College graduate 1,445 (13) 147 (10) 1,022 (71) 244 (17) 20 (1) 12 (<1) . 
Unknown 2,377 (22) 291 (12) 1,353 (57) 548 (23) 155 (7) 30 (1) . 
Family History Breast 
Cancer  
 
  
  
 
No 8,701 (80) 881 (10) 5,266 (61) 1,877 (22) 547 (6) 130 (1) . 
Yes 1,276 (12) 122 (10) 764 (60) 280 (22) 94 (7) 16 (1) . 
Unknown 940 (9) 66 (7) 540 (57) 260 (28) 48 (5) 26 (3) . 
BIRADS        . 
0Additional imaging 7,763 (71)  827 (11) 4,743 (61) 1,633 (21) 459 (6) 101 (1) . 
3Probably benign 1,906 (17) 143 (8) 1,096 (58) 501 (26) 124 (7) 42 (2) . 
4Suspicious  1,033 (9) 84 (8) 628 (61) 213 (21) 85 (8) 23 (2) . 
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Total 
Insurance 
Private 
Only 
Medicare & 
Private Medicare Only 
Medicare & 
Medicaid 
Medicaid 
Only 
No 
Insurance† 
N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
5Suggestive of 
malignancy 215 (2) 
 
15 (7) 103 (48) 70 (33) 
 
21 (10) 
 
6 (3) . 
* cells sizes <11 suppressed 
† women aged 65+ with no insurance excluded due to small sample size n=24 
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Table 18. Most Common Imaging and Biopsy Pathway Use for Diagnostic Follow-up after a 
Positive Screening Mammogram by Insurance Status, Stratified by under 65 Years and 65 
Years and Older between 1995-2010 in North Carolina 
Insurance 
 
 
Total 
Follow-up pathway 
1 
Diagnostic 
Mammography 
only* 
3 Diagnostic 
Mammography, 
Ultrasound* 
4 
Diagnostic 
Mammography,  
Biopsy* 
 
 
 
No follow-
up/unobserved* 
N (%)† N (%) N (%) N (%) N (%) 
All Ages 38,190 (100) 28,795 (75) 4,215 (11) 2,973 (8) 2,207 (6) 
Age <65      
<65 Total 28,228 (100) 21,053 (75) 3,111 (11) 2,185 (8) 1,879 (7) 
Private 
Only 
25,049 (89) 18,915 (76) 2,716 (11) 1,808 (7) 1,610 (6) 
Medicare 
& Private 
 
516 (2) 
 
356 (69) 
 
75 (15) 
 
67 (13) 
 
18 (3) 
Medicare 
Only 
571 (2) 384 (67) 70 (12) 70 (12) 47 (8) 
Medicare 
& 
Medicaid 
 
425 (2) 
 
278 (65) 
 
58 (14) 
 
62 (15) 
 
27 (6) 
Medicaid 
Only 
832 (3) 585 (70) 100 (12) 97 (12) 50 (6) 
No 
Insurance 
835 (2) 535 (64) 92 (11) 81 (10) 127 (15) 
Age 65+      
65+ Total 10,608 (100) 7,742 (73) 1,104 (10) 1,165 (11) 597 (6) 
Private 
Only 
1,046 (10) 774 (74) 98 (9) 76 (7) 98 (9) 
Medicare 
& Private 
 
6,378 (60) 
 
4,683 (73) 
 
650 (10) 
 
783 (12) 
 
262 (4) 
Medicare 
Only 
2,352 (22) 1,721 (73) 257 (11) 212 (9) 162 (7) 
Medicare 
& 
Medicaid 
 
664 (6) 
 
452 (68) 
 
79 (12) 
 
75 (11) 
 
58 (9) 
Medicaid 
Only 
168 (2) 112 (67) 20 (12) 19 (11) 17 (10) 
*p<0.05 from chi-square test 
† Row percentages 
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Table 19. Odds Ratio and 95% Confidence Intervals Predicting a Pathway that Includes 
Biopsy by Insurance Status for Women Less than 65 Years and 65 Years and Over, in North 
Carolina between 1995-2010 
<65 years Crude Adjusted* 
Insurance  Odds 
Ratio 
95% 
Confidence 
Interval 
p-
valueǂ 
Odds 
Ratio 
95% 
Confidence 
Interval 
p-
valueǂ 
Medicaid 1.82 1.47-2.26 <.01 1.10 0.77-1.56 0.61 
Medicare 1.89 1.45-2.46 <.01 1.12 0.72-1.72 0.62 
Medicare & 
Medicaid 
2.53 1.93-3.32 <.01 1.68 1.05-2.68 0.03 
Medicare & 
Private± 
1.90 1.46-2.49 <.01 1.39 0.90-2.16 0.14 
Private 1.00 
(ref) 
. . 1.00 
(ref) 
. . 
No Insurance† 1.40 1.09-1.80 <.01 0.89 0.58-1.36 0.59 
65+ years Crude Adjusted 
Insurance  Odds 
Ratio 
95% 
Confidence 
Interval 
p-
valueǂ 
Odds 
Ratio 
95% 
Confidence 
Interval 
p-
valueǂ 
Medicaid 0.93 0.53-1.63 0.81 1.53 0.57-4.11 0.40 
Medicare 0.65 0.54-0.79 <.01 0.78 0.57-1.06 0.12 
Medicare & 
Medicaid 
1.08 0.82-1.41 0.58 0.90 0.56-1.45 0.67 
Medicare & 
Private±  
1.00 
(ref) 
. . 1.00 
(ref) 
. . 
Private 0.58 0.44-0.77 <.01 0.53 0.35-0.79 <.01 
No Insurance† - - - - - - 
*Fully adjusted models include race, urban/rural residence, education, breast density, age, BIRADS assessment 
at index positive screen, first degree relative with breast cancer, history of biopsy, facility type, and time since 
last mammogram 
ǂ α<0.05 considered statistically significant 
†65 years and over with no insurance removed from analyses due to small numbers 
± Referent group for 65+ years changes to Medicare & Private because it was the most populous group in that 
age category 
  
 119 
Table 20. Odds Ratio and 95% Confidence Intervals Predicting a Pathway that Includes 
Biopsy by Demographic Characteristics for Women Less than 65 Years and 65 Years and 
Over, in North Carolina between 1995-2010 
<65 years  
 
 
Race 
Odds 
Ratio* 
95% 
Confidence 
Interval 
p-valueǂ 
Black, non-Hispanic 1.00 0.82-0.23 0.96 
White, non-Hispanic (ref) 1.00 . . 
Other 0.72 0.44-1.16 0.18 
Unknown 0.94 0.65-1.36 0.75 
Age    
40-44 (ref) 1.00 . . 
45-49 1.08 0.87-1.35 0.47 
50-54 1.45 1.15-1.82 <0.01 
60-64 1.61 1.26-2.06 <0.01 
Education    
<High School 0.80 0.58-1.10 0.17 
High School (ref) 1.00 . . 
Some College 1.00 0.82-1.23 0.97 
College  0.72 0.58-0.88 <0.01 
Unknown 0.99 0.79-1.25 0.97 
65+ years  
 
 
Race 
Odds 
Ratio* 
95% 
Confidence 
Interval 
p-valueǂ 
Black, non-Hispanic 0.79 1.82-1.14 0.21 
White, non-Hispanic (ref) 1.00 . . 
Other 0.52 0.19-1.41 0.20 
Unknown 0.81 .46-1.44 0.48 
Age    
65-69 (ref) 1.00 . . 
70-74 1.05 0.79-1.40 0.72 
75+ 0.89 0.68-1.16 0.38 
Education    
<High School 0.82 0.56 0.32 
High School (ref) 1.00 . . 
Some College 1.18 0.87-1.61 0.28 
College  1.40 0.96-2.04 0.08 
Unknown 1.18 0.82-1.69 0.37 
*Fully adjusted models include race, urban/rural residence, education, breast density, age, BIRADS assessment 
at index positive screen, first degree relative with breast cancer, history of biopsy, facility type, and time since 
last mammogram 
ǂ α<0.05 considered statistically significant 
†65 years and over with no insurance removed from analyses due to small numbers 
± Referent group for 65+ years changes to Medicare & Private because it was the most populous group in that 
age category 
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CHAPTER 7: DISCUSSION 
Summary of Main Findings 
Aim 1  
We examined insurance as a predictor of time to initial diagnostic follow-up in a large 
population-based mammography registry and found that among women less than 65 years of 
age, women without insurance experienced a longer time to initial diagnostic follow-up 
compared to women with private insurance. Among women ages 65 and older, women with 
private only insurance experienced a faster time to initial diagnostic follow-up compared 
with women with Medicare and private insurance. These women may be more economically 
advantaged with increased access to care. In the multivariable logistic regression models, 
uninsured women less than 65 years of age were 1.59 times more likely to experience a delay 
when compared to the privately insured in the same age group. There were no observed 
statistically significant associations between insurance status and delay among women 65 
years of age and over.  
Aim 2 
In order for patient level interventions and patient level care to be successful we must 
be able to enumerate the diagnostic pathways a woman may experience after a positive 
screening mammogram the most common diagnostic resolution pathways following a 
positive screening mammogram were: 1) diagnostic mammography only; 2) diagnostic 
mammography, ultrasound; and 3) diagnostic mammography, biopsy. We also observed 
differences in the diagnostic follow-up pathway by insurance status in both age groups. 
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Women 65 years of age and under were less likely to experience a biopsy. The original 
hypothesis for the present study was that women reporting private insurance would be more 
likely to experience a biopsy as private insurance is generally associated with increased 
access to care and improved health care outcomes when compared to other insurance groups. 
Since we did not observe this result, it remains to be seen the underlying mechanisms may be 
influencing the use of biopsy after a positive screening mammogram. Implication for women 
of varying insurance status also remains to be seen. Alternative hypotheses must be 
considered such as radiologist’s preferences and the impact of the facility providing the 
follow-up care. 
Methodological Consideration 
Comparing the findings from studies is made difficult because studies use varying 
definitions for diagnostic follow-up (time until first exam versus time until the positive 
screen is completely resolved) as well as varying cutoffs for timely resolution (for example 
30 or 60 days). Many studies investigate follow-up after a positive screening mammogram in 
terms of delayed follow-up, which is generally defined as a follow-up time extending past 60 
days from the positive screening mammogram. These studies generally present odds ratios 
with the follow-up outcome dichotomized at 60 days. Studying follow-up only in terms of 
delay may not be as informative since it does not highlight factors contributing to delay or 
recommendations by the radiologist for follow-up, which may legitimately extend time to 
follow-up. After a positive mammogram a woman can undergo a variety of clinical follow-up 
events (additional mammography, breast ultrasound, Magnetic Resonance Imaging or MRI, 
and biopsy) in order to diagnosis a breast cancer or confirm a benign result. Depending on 
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these clinical recommendations, what is termed as a delay in many studies could in fact be 
acceptable follow-up. 
Limitations  
It is important to note several limitations of the proposed study. It is possible that 
some follow-up visits may not be captured in the CMR data (i.e. a woman receives follow-up 
examination outside of the state or at a non-participating mammography facility). Also, it 
will be impossible for us to determine the reasons for any delay observed among women 
included in the registry. It is possible however, to compare the radiologist’s 
recommendations for follow-up with the actual pathway to diagnostic follow-up.  
Another limitation in this study is the lack of reporting of insurance status by some 
facilities as well as lack of coverage of all NC facilities providing mammograms. It should 
also be noted that in this study there are unmeasured confounder; namely, income, which is 
not collected by facilities, and co-morbid conditions of women receiving mammograms. It is 
possible that co-morbid conditions may impact the patient’s healthcare outcomes such as the 
ability to undergo diagnostic procedures. Further, results from the study should be interpreted 
with the knowledge that the study population includes only women from NC.  
Strengths  
This study reflects many strengths and improvements to the existing literature. We 
assess the association between time until diagnostic follow-up after a positive screening 
mammogram and insurance status among women included in a racially diverse, population-
based mammography registry utilizing mammography imaging results and radiologist 
recommendation for follow-up examination. The Carolina Mammography Registry is a 
prospective population-based mammography study. The data are longitudinal providing the 
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opportunity to follow individual women receiving screening mammograms and subsequent 
breast imaging procedures within the state for an extended period of time. Prior studies have 
relied on questionnaires, administrative databases set up for billing purposes, or medical 
record review. Administrative data sources often rely on a medical billing code, which only 
indicates that a procedure was completed. Patient questionnaires or medical records may lack 
complete dates of services to ensure sufficient documentation of time until diagnostic follow-
up. CMR data contains detailed information on breast imaging procedures including the date 
of procedure as well as the imaging result and the radiologist recommendation. Additionally, 
for each woman the data contain comprehensive breast cancer risk factor data such as breast 
density.  
Public Health Implications 
Lack of insurance may be an impediment to timely follow-up after breast cancer 
screening mammography and may contribute to disparities in breast cancer care. In this 
study, we did not find that Medicaid insurance was associated with a longer time to initial 
diagnostic follow-up after a positive screening mammogram, regardless of age group. Results 
of this study may be used to aid in our understanding of the disparities observed in the breast 
cancer care continuum. These results may be particularly useful for public health 
professionals planning or modifying patient navigation initiatives with the goal of identifying 
ways to help women complete follow-up. These results may aid in the identification of target 
populations that may be at risk of experiencing a delay in screening follow-up may benefit 
from these initiatives.  
In many studies of breast cancer outcomes, Medicaid enrollment is a predictor of poor 
health outcomes. A reason for the difference we observed could be that this study only 
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includes women who have sought some sort of initial healthcare in the form of their initial 
screening mammogram. It may be the case that these women could be different than the 
general population in terms of healthcare seeking behaviors. Screening may also be different 
than health cancer health outcomes because breast cancer screening for women is widely 
publicized and accepted. The USPSTF and the American Cancer Society recommended regular 
screening and most insurances are required to cover a screening mammogram. 
This work may also have policy implications. National guidelines for screening 
mammography may impact the availability of coverage for screening mammography by 
insurance entities. Co-payments, co-insurance, or other aspects of insurance coverage such as 
pre-approval for imaging and/or biopsy after the initial positive screening mammogram may 
vary by insurance provider and may limit access to follow-up care. In other words, insurance 
coverage often does not equate to an elimination of out of pocket expenses for the patient. 
Access to health insurance is a modifiable factor. This may be important in light of the 
passage of the Affordable Care Act (ACA) and Medicaid expansion which aims to extend 
health insurance coverage to the uninsured by making coverage more accessible and 
affordable. 
In summary, to maximize the benefits of screening mammography it is important that 
women receive appropriate and timely follow-up after a positive screening mammogram, 
especially if the follow-up delays necessary treatment. Additionally, it is important to be able 
to enumerate the series of follow-up women experience after a positive screening 
mammogram, and understand how insurance impacts follow-up after a positive screening 
mammogram.  
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